Tuberous Sclerosis-associated enamel pitting and gingival fibromas: Familial vs. sporadic disease; genotype-phenotype correlations by Dock, Murray
TUBEROUS SCLEROSIS-ASSOCIATED ENAMEL PITTING AND GINGIVAL 
FIBROMAS: FAMILIAL VS. SPORADIC DISEASE; 
GENOTYPE-PHENOTYPE CORRELATIONS 
by 
Murray Dock 
Submitted to the Graduate Faculty of the School of 
Dentistry in partial fulfillment of the requirements 
for the Degree of Master of Science in Dentistry 
Indiana University School of Dentistry, 2000. 
ii 
Thesis accepted by the faculty of the Division of Pediatric Dentistry, Indiana 
University School of Dentistry, in partial fulfillment of the requirements for the degree of 
Master of Science in Dentistry. 
David R. A very 
Brian J. Sanders 
Susan Zunt 
Elizabeth Schorry 
David N. Franz 
Jeffrey A. Dean 
Chair of the Committee 
Date __________________________________ _ 
iii 
ACKNOWLEDGMENTS 
IV 
I dedicate this thesis to my loving and absolutely fabulous wife, Anita, and to my 
children, Jeremy and Adam, whom I cherish. They have helped me to maintain the 
necessary balance between family, work and education. Without their loving support and 
sacrifice, completing this graduate degree would not have been possible . . They are what I 
live for. 
My parents, Ben and Gert Dock, have provided constant, unconditional support 
and encouragement throughout my entire education. I cannot express enough gratitude 
for all they have done for me. 
I am deeply indebted to the administration at Indiana University School of 
Dentistry as well as Children's Hospital Medical Center, Cincinnati, Ohio for giving me 
the opportunity and support to complete this degree. 
Sincere thanks are also extended to the faculty members and staff of the Division 
of Pediatric Dentistry at Children's Hospital Medical Center for giving me the time and 
space to complete my studies. Without their understanding, support and sacrifice, 
completing the required coursework and research would not have been possible. 
I am deeply grateful to Dr. Anna Weber, the TSC neuropsychologist at Children's 
Hospital Medical Center, for being my Cincinnati advisor for this thesis. She was very 
instrumental in assisting with data manipulation and interpretation and was a constant 
source of support throughout the writing phase of the project. I offer her a very special 
thank-you for her patience and encouragement. 
v 
Appreciation is also offered to the members of the Tuberous Sclerosis Center of 
the Division of Neurology at Children's Hospital Medical Center. I would like to thank 
Dr. David Franz, neurologist and director of the Tuberous Sclerosis Center, for initially 
involving me in this collaborative research project and for serving as a graduate 
committee member on my behalf. His never-ending encouragement and advice 
throughout the study is deeply appreciated. The study coordinator, Gail Chuck, was 
instrumental in scheduling patient examinations, as well as tracking genotype data from 
Brigham and Women's Hospital. Without her efforts, this project could not have been 
completed in a timely manner. I am also appreciative of the efforts of the clinic nurse 
practitioners, Cindy Tudor, RN, PNP, and Jennifer Leonard, RN, PNP, for their 
assistance with patient flow and data input. 
I am thankful to Dr. John Bissler, a Children's Hospital nephrologist and 
consultant to the Tuberous Sclerosis Center for his guidance and for allowing me to 
spend time in his lab to gain an understanding of DNA extraction methods. 
I would also like to thank Dr. David Kwiatkowski for his advise in study design 
and mutation grouping and for allowing me to spend time in his lab at Brigham and 
Women's Hospital to obtain knowledge of DNA mutational analysis. 
Appreciation is offered to Dr. Elizabeth Schorry, the TSC clinical geneticist, for 
serving on my graduate committee. She offered much guidance in study design as well as 
in her critique of the final thesis. Discussions with Dr. Schorry tremendously helped in 
gaining an understanding of the genetics of tuberous sclerosis. She was an important 
member of my graduate committee. 
vi 
I would like to thank Dr. Judy Bean for all of her efforts in statistical analysis. I 
appreciate the time spent with me from the start to the completion of the project in 
helping to determine statistical methods as well as interpretation of the analysis. 
A special thank you to Claudette Maurer for her knowledge and skill in typing 
and formatting this manuscript. She was always accessible and extended herself above 
and beyond in making sure that all deadlines were met. 
Finally, I would like to extend gratitude to other members of my graduate 
committee to include Drs. Jeffrey Dean, David Avery, Susan Zunt, and Brian Sanders. 
They provided constant support, encouragement and tremendous flexibility throughout 
my graduate studies. Without their efforts, my graduate training would not have been 
possible, and I am very appreciative. 
vii 
TABLE OF CONTENTS 
viii 
Introduction ..................................................................................................................... 1 
Review of Literature ........................................................................................................ 5 
Materials and Methods .................................................................................................. 23 
Results .......................................................................................................................... 31 
Figures and Tables ....................................................................................... : ................ 40 
Discussion ..................................................................................................................... 90 
Summary and Conclusions ............................................................................................ 97 
References .................................................................................................................. 101 
Appendix .................................................................................................................... 108 
Abstract ....................................................................................................................... 111 
Curriculum Vitae 
ix 
LIST OF ILLUSTRATIONS 
X 
Figure 1. Facial angiofibromas characteristic of 
Tuberous Sclerosis Complex ............................................................... 41 
Figure 2. Enamel pitting. Pinpoint size enamel pitting 
(A) and crater size enamel pitting (B) characteristic 
of tuberous sclerosis complex. Red dye has become 
entrapped in the pits enhancing their recognition ................................. 42 
Figure 3. A gingival fibroma in a patient with Tuberous 
Sclerosis Complex ............................................................................... 43 
Figure 4. Total number of patients examined with a clinical 
diagnosis of Tuberous Sclerosis Complex (TSC) by 
gender, age and dentition ....................................................... .-............. 44 
Figure 5. Occurrence of enamel pitting in patients in the primary, 
mixed and permanent dentitions .......................................................... 45 
Figure 6. Total number of primary and permanent teeth 
examined affected by enamel pitting ................................................... 46 
Figure 7. Distribution of pinpoint vs. crater size enamel pitting 
affecting primary and permanent teeth examined ................................. 4 7 
Figure 8. Occurrence of enamel pitting affecting maxillary and 
mandibular arches in primary and permanent teeth 
examined ............................................................................................. 48 
Figure 9. Occurrence of enamel pitting affecting anterior and 
posterior arch positions in primary and permanent 
teeth examined .................................................................................... 49 
Figure 10. Permanent teeth affected by enamel pitting 
(percentage by tooth) ........................................................................... 50 
Figure 11. Primary teeth affected by enamel pitting 
(percentage by tooth) ........................................................................... 51 
Figure 12. Average number of enamel pits per primary 
tooth examined .................................................................................... 52 
Figure 13. Average number of enamel pits per permanent 
tooth examined .................................................................................... 53 
XI 
Figure 14. Average number of enamel pits per affected patient in 
the primary, mixed, and permanent dentitions ..................................... 54 
Figure 15. Percent of patients examined with gingival 
fibromas in the primary, mixed, and 
permanent dentitions ........................................................................... 55 
Figure 16. Occurrence of gingival fibromas affecting maxillary 
and mandibular arches in primary and permanent 
teeth exa1nined .................................................................................... 56 
Figure 17. Occurrence of gingival fibromas affecting anterior and 
posterior arch positions in patients in the primary, mixed, 
and permanent dentitions ........................................................ ~ ............ 57 
Figure 18. Average number of gingival fibromas per affected 
patient in the primary, mixed, and permanent 
dentitions. T -tests compare the means for mixed 
and permanent dentitions ..................................................................... 58 
Table I. Enamel pitting and gingival fibromas ............................................. 59-62 
Table II. Phenotype variables ....................................................................... 63-67 
Table III. Mutation/familial vs. sporadic disease ........................................... 68-69 
Table IV. Key to statistical testing ...................................................................... 70 
Table V. T-test for angiomyolipomas (AML) and oral variables ........................ 71 
Table VI. T -test for polycystic kidney disease (PKD) and 
oral variables ...................................................................................... 72 
Table VII. T -test for cardiac rhabdomyomas and oral variables ............................ 73 
Table VITI. T -test for cardiac arrhythmias and oral variables ................................. 7 4 
Table IX. T -test for facial angiofibromas and oral variables ................................ 75 
Table X. T-test for retinal lesions and oral variables .......................................... 76 
Table XL T -test for seizures vs. no seizures and oral variables ............................ 77 
xii 
Table XII. T -test for familial (F) vs. sporadic (S) TSC 
and oral variables ................................................................................ 78 
Table XIII. T -test for non truncating (Nt) vs. truncating 
(T) mutations and oral variables .......................................................... 79 
Table XIV. Chi-square test for oral fibromas vs. systemic variables ....................... 80 
Table XV. Correlation coefficients for phenotype variables 
vs. oral variables ............................................................................ 81-83 
Table XVI. Analysis of variance testing (ANOV A) for seizure 
severity and cognitive impairment vs. oral variables .............. _ .............. 83 
Table XVII. Key to summary of statistical tests ...................................................... 84 
Table XVIII. Summary chart of statistical tests for oral findings 
vs. phenotype variables .................................................................. 85-87 
Table XIX. Summary chart of statistical tests for oral findings 
vs. TSC familial and sporadic disease and mutation type ..................... 88 
INTRODUCTION 
2 
Tuberous sclerosis is an inherited disorder with a gene frequency estimated to be 
as high as 1 in 6,000 to 1 in 10,000. 1 Affected individuals have a wide variety of clinical 
symptoms usually involving benign tumor growths (hamartomas) of different parts of the 
body. The brain, heart and kidney are most frequently affected with a wide variability in 
the expression of this disorder. Individuals may carry the affected gene and.have few or 
no clinical symptoms. Other individuals may be subject to seizures, autism, mental 
retardation, congenital heart disease, kidney tumors, renal failure, hypertension, skin 
lesions, and pitting of enamel as well as oral fibromas? There are two genes that are 
associated with tuberous sclerosis: TSC 1 on chromosome 9p34, and TSC2 on 
chromosome 16p13.3.3 Two-thirds of TSC cases are sporadic and are thought to 
represent new mutations with the majority being TSC2. The remainder are familial with 
an equal distribution between TSC1 and TSC2, and these patients tend to be less severely 
affected clinically than individuals with sporadic TSC.4 While many people with TSC 
are thought to have spontaneous mutations, the genes are also known to exhibit extremely 
variable expression. Even though penetrance is very high, there are often individuals 
with some of the manifestations of TSC but insufficient involvement to make a definitive 
diagnosis. It is unknown why there is such variability in the symptoms expressed by the 
people who carry one of these mutations. 
The TSC2 gene was cloned in 1993 and the TSC1 gene cloned in 1997.5 The full 
genomic sequence of both genes is now currently available with the TSC2 gene being 
significantly more complex than the TSC1 gene. Thus far, over 148 unique mutations in 
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TSC1 and 251 unique mutations in TSC2 have been identified. Clinically it is not 
possible to distinguish patients with TSC1 from patients with TSC2, and there have been 
only preliminary genotype-phenotype correlations established. 
There have been many reports of the oral manifestations of tuberous sclerosis. It 
is clearly established that affected individuals demonstrate enamel pitting and fibromas of 
the oral tissues at a frequency greater than that of the population as a whole. There have 
been no studies that have compared the oral findings of enamel pitting and oral fibromas 
in familial and sporadic TSC, or that have looked at genotype-phenotype correlations as 
related to oral findings. Additionally, there have been no reports relating these oral 
findings in TSC patients to other disease variables (e.g. IQ, seizure activity, skin 
angiofibromas, cardiac involvement, and renal disease). 
The purpose of this investigation was: 
1. To study the incidence and severity of enamel pitting and gingival fibromas in 
patients with a confirmed diagnosis of TSC. 
2. To compare the incidence and severity of enamel pitting and incidence of oral 
fibromas in sporadic vs. familial cases of TSC. 
3. To correlate the incidence of enamel pitting and oral fibromas in patients with 
TSC2 to the following groups of mutations: 
a. Truncating mutations (small insertions and deletions, nonsense, splice site) 
and large genomic deletions and rearrangements. 
b. Nontruncating mutations (missense point mutations and in-frame 
deletions). 
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4. To correlate the incidence and severity of enamel pitting and incidence of oral 
fibromas in individuals with TSC to phenotype severity as measured by intellectual 
ability, seizure activity, skin involvement, cardiac involvement, retinal lesions and kidney 
disease. 
The hypothesis is that the incidence and severity of enamel pitting and the 
incidence of gingival fibromas in individuals with TSC sporadic disease is greater than in 
individuals with TSC familial disease. Additionally, the incidence and severity of these 
oral findings is related to phenotype severity and may be associated with specific 
mutation types. 
5 
REVIEW OF LITERATURE 
EPIDEMIOLOGY AND HISTORY OF 
TUBEROUS SCLEROSIS COMPLEX 
6 
Tuberous Sclerosis Complex (TSC) is an autosomal dominant disorder and is 
included in a group of syndromes known as the neurocutaneous syndromes, 
neurodermatoses, ectodermoses, or phakomatoses.6 Other major disorders in this group 
include von Recklinghausen' s generalized neurofibromatosis, and Sturge Weber 
syndrome. TSC-affected individuals have a wide variety of clinical symptoms usually 
involving hamartomas of different parts of the body. A hamartoma is defined as "a focal 
malformation that resembles a neoplasm, grossly or even microscopically, but results 
from faulty development in an organ; composed of an abnormal mixture of tissue 
elements, or an abnormal proportion of a single element, normally present in that site 
which develop and grow at virtually the same rate as normal components, and are not 
likely to result in compression of adjacent tissue."7 Unlike other neurocutaneous 
diseases, hamartomas can develop in every organ system of the body but are especially 
prevalent in the brain, eyes, kidneys, heart, and skin.2•8 The lungs, skeleton, endocrine 
glands, and the tissues of the oral cavity are occasionally affected.3•9 Hamartomas 
involving the skeletal muscles have not been reported. 
The incidence of TSC is estimated to be between 1 in 6000 to 1 in 10,000 births. 10 
The clinical expression is extremely variable and unpredictable; therefore, the frequency 
of diagnosed cases is likely to under represent true prevalence. 10 Both sexes are affected 
equally with two-thirds of cases representing spontaneous mutations. Penetrance is 
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estimated to be approximately 95 percent; however, there have been reported cases where 
neither parent was apparently affected. These cases, after rigorous clinical evaluation and 
molecular genetic analysis, have recently been disproved.4•5 It is likely that the reported 
high spontaneous mutation rate may in fact represent the variability in expression of the 
gene and the associated difficulty in diagnosis of the disease. 
Delineating the full extent of TSC involved a multidisciplinary effort, with 
contributions from pathologists, neurologists, dermatologists, geneticists, radiologists, 
and dentists of the past and present century. 11 Von Recklinghausen described a neonate 
with characteristics of tuberous sclerosis in 186212; however, the name tuberous sclerosis 
was introduced by Bourneville in 1880 after reporting on a three-year-old patient with 
mental retardation, seizures and facial angiofibromas. 8•13 He described the characteristic 
brain lesions (hamartomas) as potato or root-like in consistency, hence the name tuber. 
Tubers are regions of disorganized cortical lamination containing heterogeneous cellular 
elements including abnormal and normal appearing neurons, astrocytes and giant cells. 
Adenoma sebaceum facial lesions (angiofibromas) and the "Shagreen" patches were 
initially described by Pringle in 1890. Vogt, in 1908, proposed the "classic triad" of 
seizures, mental retardation, and adenoma sebaceum (facial angiofibromas) and noted 
that cardiac and renal tumors were part of the disease. 11 This "triad" of symptoms has 
been frequently cited in the literature as diagnostic for TSC but is misleading. Recent 
studies have shown that the full triad is evident in only about one-third of patients. 14•15 
The diagnosis of TSC is dependent on a thorough clinical examination of 
cutaneous features along with cranial computed tomography, magnetic resonance 
imaging, echocardiography and renal ultrasound. As with other neurogenetic disorders, a 
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definitive diagnosis will ultimately rest on demonstration of specific genetic 
abnormalities, in addition to clinical features? Identification of genetic mutations in 
TSC, however, remains limited to research applications, so that diagnosis continues to 
rest on recognition of characteristic clinical signs and symptoms.2 TSC diagnostic 
criteria was initially established by Dr. Manuel R. Gomez and was used for many years. 
The most recent diagnostic criteria for tuberous sclerosis was developed at the Tuberous 
Sclerosis Consensus Conference in 1998. 16 
REVISED DIAGNOSTIC CRITERIA FOR 
TUBEROUS SCLEROSIS COMPLEX 
Major Features 
1. Facial angiofibromas or forehead plaque. 
2. Nontraumatic ungual or periungual fibroma. 
3. Hypomelanotic macules (more than three). 
4. Shagreen patch (connective tissue nevus). 
5. Multiple retinal nodular hamartoma. 
6. Cortical tuber (see "a" on next page). 
7. Subependymal nodule. 
8. Subependymal giant cell astrocytoma. 
9. Cardiac rhabdomyoma, single or multiple. 
10. Lymphangiomyomatosis (see "b" on next page). 
11. Renal angiomyolipoma. 
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Minor Features 
1. Multiple randomly distributed pits in dental enamel. 
2. Hamartomatous rectal polyps (see "c" below). 
3. Bone cysts (see "d" below). 
4. Cerebral white matter radial migration lines (see "c, d, e" below). 
5. Gingival fibromas. 
6. Nonrenal hamartoma (see "c" below). 
7. Retinal achromic patch. 
8. "Confetti" skin lesions. 
9. Multiple renal cysts (see "c" below). 
a. When cerebral cortical dysplasia and cerebral white matter migration tracts 
occur together, they should be counted as one rather than two features of tuberous 
sclerosis. 
b. When both lymphangiomyomatosis and renal angiomyolipomas are present, 
other features of tuberous sclerosis should be present before a definite diagnosis is 
assigned. 
c. Histological confirmation is suggested. 
d. Radiographic confirmation is sufficient. 
e. One panel member at the 1998 conference felt strongly that three or more 
radial migration lines should constitute a major sign. 
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MAKING THE DIAGNOSIS 
Definite TSC: Either two major features or one major feature plus two minor features. 
Probable TSC: One major plus one minor feature. 
Possible TSC: Either one major feature or two or more minor features. 
SYSTEMIC PHYSICAL FINDINGS 
Pathologically, tuberous sclerosis is a disorder of cellular migration, proliferation, 
and differentiation. 17 TSC affects different organ systems in various ways and many of 
the manifestations are age dependent. The disorder results in lesions including 
subependymal brain nodules and calcifications, astrocytomas, retinal phacomas, sclerotic 
bone lesions, hamartomas or cystic lesions of the brain, heart, lungs, kidneys, spleen, 
liver, uterus, and soft tissues, and dental enamel pitting and oral fibromas. 
The most severely affected system is the central nervous system resulting in 
cerebral manifestations in up to 95 percent of affected individuals.2 Brain involvement 
includes cerebral hamartomas, subependymal nodules, and subependymal giant cell 
astrocytomas. The hamartomas, or tubers, are regions of abnormal cortical architecture 
with distinctive large neuronal cells 18 occurring at the gray-white junction. Varying in 
size from millimeters to several centimeters, tubers are rounded or wart-like protrusions 
of single or adjacent gyri, very firm to touch and pale in color. 8•13•19•20 Tubers are found 
primarily in the frontal-parietal cortex and cerebellum and rarely affect the brainstem and 
spinal cord. The number and size of the cortical tubers varies greatly between patients 
and correlates with the severity of neurologic manifestations. Goodman and colleagues21 
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noted statistically significant associations using the cortical tuber count detected on MRI 
scans as a biomarker to predict the severity of cerebral dysfunction in TSC patients. 12 
Goodman's findings suggest that patients with moderate to severe cerebral dysfunction 
are more likely to have more than 7 MRI-detected tubers than mildly affected TSC 
patients. Subependymal nodules (SEN) are nodular lesions occurring in approximately 
80 percent of TSC patients, are found mostly on the surfaces of the lateral ventricles, and 
are typically asymptomatic. SENS that continue to grow form subependymal giant cell 
astrocytomas (SEGAs).22 SEGAs typically arise in the subventricular region of the brain, 
most commonly in the lateral ventricle, and can cause hydrocephalus and increased 
intracranial pressure.23-25 SEGAs occur in 5 to 14 percent of TSC patients.26•27 
The predominant neurologic sequelae of TSC are seizures, mental retardation, and 
behavioral disturbances. 12 Seizures are a common manifestation occurring in close to 80 
percent of patients, often develop prior to one year of age, and are more common in 
males. Patients with generalized seizures and severe mental retardation correlate to a 
larger number of tubers in the brain. 17 Intellectual disability occurs in approximately 50 
percent of the patients and likewise is seen more often in males. While most mentally 
retarded patients also suffer from seizures, many tuberous sclerosis patients have seizures 
but are not intellectually impaired. 12'28 Patients who develop seizures during their first 
five years of life seem to be the most likely to develop learning difficulties. Various 
behavioral problems occur in over 50 percent of TSC patients and include autism and 
attention-deficit with hyperactivity disorder. Other behavioral problems include strong 
anger or rage reaction, stubbornness, lethargy, and interrupted sleep patterns. 
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Retinal lesions can occur in up to 75 percent of TSC patients and include 
achromic patches, plaque-like hamartomas, and calcified astrocytomas. Most of the 
retinal lesions are of no clinical significance; however, there have been some reports of 
associated visual compromise. 28 
Cutaneous lesions occur in up to 95 percent of patients with TSC and include 
hypomelanotic macules (ash leaf spots), facial angiofibromas (adenoma sebaceum), 
ungual fibromas, and subcutaneous thickening (shagreen patches). Hypomelanotic 
patches occur at all ages and are seen in at least 90 percent of patients. The patches, as 
large as 5 em in length, are most easily detected with an ultraviolet light (Wood's light). 
These lesions are frequently seen in the general population and are thus not 
pathognomonic of TSC. Facial angiofibromas, previously referred to as adenoma 
sebaceum, are papillary lesions that are pink in color and consist of blood vessels, fibrous 
tissue and sclerotic collagen (cutaneous hamartomas), typically in a butterfly distribution 
on the face, cheeks, nasal folds, and chin. The lesions usually do not become apparent 
until late childhood or adolescence.9•12 A variation of the facial angiofibroma is the 
forehead fibrous plaque. This is a slightly elevated flesh-colored or yellowish plaque 
seen in slightly less than 20 percent of TSC individuals. Ungual fibromas appear during 
adolescents and adulthood and occur in approximately 25 percent of affected patients. 
These growths are fairly specific for TSC and are a major diagnostic feature. Shagreen 
patches (connective tissue nevus) are areas of thickened subcutaneous tissue manifested 
as raised yellowish-brown, pink, or green plaques or nevi found usually on the patient's 
lower back. These lesions are not specific for TSC but are considered a major diagnostic 
feature. 
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Renal involvement includes angiomyolipomas and multiple epithelial cysts 
(polycystic kidney disease). Angiomyolipomas are vascular tumors consisting of blood 
vessels, smooth muscle, and adipose tissue. 23 Angiomyolipomas can occur in up to 80 
percent of patients, frequently manifest bilaterally, and can increase in size over time 
especially in females. Complications of these lesions include malignant transformation, 
pain, and severe hemorrhage. Renal cysts occur in 15 to 20 percent of TSC-affected 
individuals and result in renal failure in less than 5 percent of affected patients. 
Polycystic renal disease tends to occur in infants and young children, whereas 
angiomyolipomas, with or without cysts, are more common in adults. 14 In fact, in a 
longitudinal study conducted by Ewalt et al./9 half of the renal cysts observed on initial 
evaluation spontaneously disappeared on follow-up examination. This phenomenon has 
not been noted to occur with angiomyolipomas. 
Bone involvement has been noted in 66 percent of patients affected with TSC.30 
Osseous findings reported include multiple areas of sclerosis, especially in the calvarium, 
spine, and pelvis, cyst-like lesions, and periosteal new bone formation in the hands and 
feet. 31 
Cardiac lesions consist of cardiac rhabdomyomas and are a frequent occurrence at 
or before birth. Fifty to 60 percent of individuals with TSC have evidence of cardiac 
disease, mostly rhabdomyomas.9 These lesions usually have little clinical significance 
and tend to regress over the first few years of life.2•32 Serious complications are 
uncommon and include arrhythmias, cardiomyopathy, and thromboembolic disease. 
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Pulmonary involvement is seen exclusively in women occuring in 1 to 6 percent 
of cases. 17 Lesions occur between 20 and 40 years of age and consist of either pulmonary 
cysts or lymphangioleiomyomatosis (LAM) leading to severe morbidity and mortality. 
Many of the manifestations of tuberous sclerosis are age-dependent. Cardiac 
rhabdomyomas are frequently seen in infancy, which may give rise to arrhythmias and 
alterations in blood flow, but tend to regress with age with little morbidity. Facial 
angiofibromas, ungual fibromas, renal angiomyolipomas and SEGAs appear later in 
childhood or early adulthood. 33 Mortality from TSC is most commonly from 
development of an intracerebral giant cell astrocytoma or renal bleeding from an 
angiomyolipoma. 
ORAL MANIFESTATIONS 
The oral manifestations of TSC include pitting of the enamel, soft tissue fibromas, 
osseous fibromas of the jaws, and alveolar hyperostosis. There have been numerous 
reports describing the oral findings in patients of various age ranges, and about the nature 
of enamel pitting. Dental enamel pits have been found in pediatric and all adult patients 
with TSC, compared with 7 percent of controls.34-37 There have been no reports, 
however, correlating the severity of enamel pitting, or oral fibromas, to the severity of the 
disease or to specific TSC mutations. 
Enamel pitting as a feature of tuberous sclerosis was initially described by Hoff et 
al.35 in 1975. The report included the clinical and scanning-electron microscope 
appearances of enamel defects in six patients with tuberous sclerosis. Clinically, an 
average of three pits were detected per tooth; the pits were randomly distributed, and 
15 
appeared without contralateral symmetry. Hoff described three types of defects: small 
pits ( 4 urn in diameter), indentations (up to 60 urn in diameter), and craterlike structures 
(up to 100 urn in diameter). Electron microscope examination revealed depth of the 
enamel defects ranged from one-third of the enamel thickness to the base of the 
dentinoenamel junction. At the base of the pits, amorphous loose organic material and 
calculus were noted. No dentin abnormalities were noted. The pitting was assumed to be 
due to malfunctioning of one or more ameloblasts and a defective interaction between the 
odontoblasts and ameloblasts. Hoff concluded that the pitting was pathognomonic of TSC 
and that detection was important in the early diagnosis of the complex. 
Sampson et al.38 examined 30 patients ranging from age 10 to 45+ years old with 
tuberous sclerosis for macroscopic enamel pitting. They found 48 percent of permanent 
teeth showed pitting, while none of the six patients in the primary dentition had evidence 
of pitting. Enamel pits were found predominantly on the anterior teeth, and all but two 
pits affected the facial rather than the lingual surface. He concluded that a dental survey 
for enamel pitting may be useful in patients with permanent teeth, but is less helpful in 
the pre-school child. 
Mlynarczyk39 examined 50 patients with tuberous sclerosis and 250 control 
patients. He found the incidence of enamel pitting in the permanent dentition of patients 
with tuberous sclerosis was 100 percent, whereas in the adult dentition of the control 
group the incidence was 7 percent. The pitting in the control group was not as deep and 
definite as that of tuberous sclerosis patients. Among patients with tuberous sclerosis 
younger than 11 years of age, Mlynarczyk reported an incidence of 76 percent. 
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Another study by Lygidakis and Linderbaum40 examined 36 families with TSC 
including 49 affected persons and 68 apparently unaffected first-degree relatives for 
pitted enamel hypoplasia. The study revealed enamel pitting in 71 percent of TSC 
patients and in 13 percent of the relatives. 
There have been a couple of reports that have specifically described enamel 
pitting in deciduous teeth. Ho et al. 34 in 1995 published a report after examining enamel 
pitting in 13 TSC patients aged 2.5 to 18 years with varying degrees ofTSC. A control 
group of 39 unrelated patients without TSC were also examined. A total of 77 percent of 
TSC patents revealed enamel pitting, compared with 13 percent of controls. The total 
number of enamel pits in each patient varied from 1 to 26 and increased with age. Ninety 
percent of the teeth with enamel pitting displayed one to two pits per tooth. The youngest 
patient with enamel pitting was 5 years old. All TSC patients older than 5 years and 1 
month displayed pitting. In addition, Russel et al.41 in 1996 examined shed deciduous 
teeth from 20 TSC patients for enamel pitting with a surface microscope. Enamel pitting 
was found in all 87 deciduous teeth, but in none of the 253 deciduous teeth from 142 
controls constituting patients with cerebral palsy, phenylketonuria, and Down syndrome, 
as well as healthy persons. Enamel pits were always found on the facial surface of the 
central incisors, lateral incisors, and canines, but not in any specific location on the tooth. 
Ground sections examined microscopically revealed an undisturbed pattern of 
incremental lines (Retzium striae) surrounding the pits. Additionally, Russell reported 
the macro- and microscopic studies of the operculae from patients with TSC showed a 
very irregular hyperplastic inner surface of the dental follicle. He suggested that the 
hyperplastic changes of the inner enamel epithelium may be a cause of focal disturbances 
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of the amelogenesis. He concluded that the detection of enamel pits in deciduous as well 
as in permanent teeth is a valuable clinical diagnostic tool. 
Enamel pitting is a form of hypoplasia and is not pathognomonic of tuberous 
sclerosis. Bhat reported enamel pitting as occurring twice as often than in the general 
population in patients suffering from cerebral palsy, mental retardation, and those with 
hearing defects. 42 Other conditions with enamel pitting include chemical ingestion during 
tooth formation ( eg. fluoride, tetracycline), pseudohypoparathyroidism, amelogenesis 
imperfecta, vitamin D dependent rickets, epidermolysis bullosa, tricho-dento-osseous 
syndrome, and localized trauma during tooth development. Additionally, enamel pitting 
observed in individuals with or suspected of TSC must be distinguished from pitting 
associated with normal tooth morphology as well as certain types of smooth surface 
decay. 
Other oral findings are of equal importance as diagnostic features of tuberous 
sclerosis. Oral lesions other than enamel pitting consist mainly of fibrous growths 
affecting the gingiva. They may also be found on the lips, the dorsum of the tongue, and 
the palate.43•44 Although a prevalence of 11 percent has been reported for oral fibromas, 
the true frequency of these findings may be significantly greater; one study of 39 patients 
• 
43 45 0 h I b 1· . revealed oral fibromas in 56 percent of TSC patients. · t er ora a norma ttles 
described include high palate, cleft lip and palate, macroglossia, and hyperostotic alveolar 
process.43.46 
Lygidakis43 in 1989 reported on oral fibromatosis after examining 36 families 
with TSC. The subjects consisted of 48 affected persons and 69 apparently unaffected 
parents and children along with 50 control subjects. Patients' ages ranged from 16 
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months to 62 years. Oral fibromatosis was observed in 56 percent of patients with TSC. 
None of the control subjects displayed oral fibromas. The fibromas were primarily found 
on the anterior gingiva in both jaws, were covered by normal mucosa and were of normal 
color. Severely affected patients had many large fibromas (up to 1 em in diameter) 
whereas mildly affected patients had fewer numbers and of smaller size. Within the 
group of severely affected patients, the older patients appeared to have a larger number of 
fibromas. The youngest patient with oral fibromas was 11 years old. Oral fibromas -have 
been reported to be histologically either fibromatous or papillomatous hyperplasias.43.47.48 
Damm et al.45 in 1999 reported on four patients with TSC with intraosseous 
fibrous lesions of the jaws. Radiographically the lesions were reported to be either a 
unilocular or multilocular radiolucency with well-defined or ill-defined borders. 
Histopathologically, Damm et al. described the lesions having numerous basophilic and 
slightly irregular spindle-shaped nuclei within dense fibrous connective tissue that 
revealed a swirling pattern. Similar lesions can occur in extragnathic bone. The authors 
concluded that the intraosseous fibrous proliferations represent a manifestation of 
tuberous sclerosis rather than a coincidental finding. Additionally, the authors suggest 
that radiographic studies of the jaws should be a part of the diagnostic evaluation of any 
patient suspected of having tuberous sclerosis. 
GENETICS 
TSC is characterized by genetic heterogeneity.31 .49 Linkage studies have identified 
loci for TSC on chromosomes 9q34 (TSC1) and 16p13.3 (TSC2) and suggest that they 
account for approximately equal numbers of families. 50'51 There is no evidence for 
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additional TSC loci. The TSC1 gene was identified in 1997 and spans 40 kb with 23 
exons and messenger RNA of 8600 nucleotides (See Appendix I). The gene codes for the 
TSC1 protein, hamartin, contains 1164 amino acids with a predicated mass of 130 kDa .51 
The function of hamartin is unknown. The TSC2 gene was identified in 1993 and is 
encoded by 41 exons, spanning approximately 50 kb of genomic DNA 1152 (see 
Appendix I). The 5474 nucleotide mRNA encodes the protein tuberin, which has a 
region of sequence homology to the GTPase activating protein rap1 GAP. 53 Tuberin 
functions as a rap 1 regulator possessing negative growth regulatory properties. The 
TSC2 gene is adjacent, in a tail-to-tail fashion, to the PKD 1 gene, which is the major 
gene involved in autosomal dominant polycystic kidney disease. 54 Loss of heterozygosity 
(LOH) for DNA markers for both the TSC1 and TSC2 regions suggest that both tuberin 
and hamartin act as tumor suppressors. 23 LOH in hamartoma suggest that a second 
somatic mutation may be required to produce the TSC phenotype at a cellular level and is 
consistent with the genes acting as tumor suppressors. 54 The two-hit hypothesis, as 
proposed by Knudsen, states that a germline alteration in the tumor suppressor gene, 
inherited from an affected parent, is complemented by a second somatic alteration in the 
allele inherited from the unaffected parent. 55 Development of tumors arises from two 
independent mutational events. The inactivation of both copies of the gene causes a loss 
of growth control and the cell and its progeny proliferate as a hamartoma. 56 The exact 
function and relation of the gene products is not completely understood. Tuberin might 
have important functions relevant to neuronal differentiation and development, and it is 
speculated that tuberin and hamartin may function together participating in common 
pathways.4•57 
20 
Approximately two-thirds of TSC cases are sporadic, occurring in the absence of 
a family history of the disorder. 10' 18.49 These cases are thought to arise by mutation. Jones 
reported out of 150 unrelated TSC cases studied (130 sporadic, 19 familial), 120 had 
detectable disease-causing mutations and 18 percent were at the TSC 1 locus, and 82 
percent at the TSC2locus.4 Jones also found that significantly more of the sporadic cases 
had TSC2 than TSC1 mutations. In familial cases, there is equal distribution between 
TSC 1 and TSC2 cases. It has been proposed that overall disease severity is greater in 
TSC2 than in TSC1, and this may explain the disproportionate numbers of TSC2 
mutations among sporadic cases. In fact, intellectual disability was found to be 
significantly more frequent among sporadic cases with TSC2 mutation than among those 
with TSC1 mutations.4 Jones reported that phenotypic expression in familial TSC tends 
to be more mild because severely affected individuals rarely reproduce.3 
Mutations result from either deletions, insertions, or rearrangement of the base 
pair, or nucleotide, sequence in DNA. It is the sequence of base pairs in DNA that 
determines the amino acid sequence of the encoded protein. Mutations can be defined as 
follows58•59: 
Missense mutations: An alteration in a coding sequence of DNA that results in an 
amino acid replacement in the polypeptide. 
Nonsense mutations: A mutation that changes a codon specifying an amino acid 
into a stop codon, resulting in premature polypeptide chain termination. 
Frameshift mutation: A mutation caused by the insertion or deletion of one or 
more nucleotide pairs in a gene, resulting in a shift in the reading frame of all codons 
following the mutational site. 
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Large deletions: A mutation that occurs as a result of the loss of an entire portion 
of the DNA sequence. 
Large insertions: Insertion of segments of extra bases often from another part of a 
chromosome. 
Rearrangements: Mutations resulting from segments of DNA sequence 
exchanging position with each other. 
Mutations resulting in a stop codon (mRNA codons UAG, AUU, or UGA) lead to 
the termination of polypeptide synthesis and are referred to as truncating mutations. 
Nontruncating mutations result from a change in amino acid sequence and lead to an 
alteration in the biological properties of the produced protein. 
A wide variety of underlying genetic alterations have been identified in TSC 
including large and small deletions, insertions, nonsense mutations, and missense 
mutations. Several studies have shown the great majority of germ-line mutations at the 
TSC1locus to be small truncating lesions.3•5•51 •60•61 Jones demonstrated that at the TSC2 
locus, missense changes, large rearrangements including whole-gene deletions, nonsense 
mutations, and small insertions and deletions are represented at similar frequencies. 4 
Au determined that TSC2 mutations can be divided into two groups: those 
predicted to lead to premature termination of tuberin (frameshift insertions/deletions and 
nonsense mutations) and those that do not lead to premature termination of tuberin 
(missense mutations and in-frame deletions).52 He concluded that the type of germ-line 
mutation does not influence clinical phenotype. Thus far, 148 unique mutations in TSC1 
and 251 unique mutations in TSC2 (see table) have been reported (http://zk.bwh.harvard. 
edu/projects/tsc_database/index.html).62 Fifteen or more of these have been seen 
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recurrently, but none accounts for more than 5 percent of all patients.4•5•52•60-67 Eighty-
eight percent of mutations are small changes including small deletions or insertions (38 
percent), and nonsense, splice site, or missense point mutations (50 percent). Large 
genomic deletions and rearrangements account for 12 percent of identified mutations and 
are seen primarily in TSC2.62 
Because the structure of the TSC2 gene is more complex that the TSC 1 gene, and 
its mutational spectrum more diverse, TSC2 mutation detection is more limited. 
Additionally, a substantial fraction of sporadic cases could involve mosaicism. 
Mosaicism is the phenomenon in which a fraction of, rather than all, germ-line somatic 
cells contain a mutation or chromosomal abnormality .18 Through mosaicism, it is 
possible for mutations to be present at low frequency, despite the presence of severe 
disease. This may account for the limitations of molecular diagnostic methods, and why 
relatively few mutations have been identified thus far in patients with TSC.3•18•52•60•66 
With the exception of a contiguous gene deletion syndrome involving TSC2 and 
PKDI at 16p13.1, and less mental handicap among TSC1 mutations as reported by 
Jones,3 significant differences between TSC1 and TSC2 phenotypes have not been 
demonstrated.3•50 Additionally, to date, no definitive genotype-phenotype correlation has 
been established. With the identification of TSCI and TSC2 genes, along with increasing 
sophistication of mutation detection, it should be possible to more accurately analyze 
phenotype differences in sporadic versus familial cases as well as evaluate for genotype 
correlation. 
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METHODS AND MATERIALS 
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This study is part of a larger IRE-approved investigation (CHMC 98-1-4) at 
Children's Hospital Medical Center, Cincinnati, Ohio, by the Department ofNeurology, 
"Genotype/Phenotype Analysis in Individuals with Tuberous Sclerosis and Their Family 
Members." The goal of this study is to determine if any genotype/phenotype correlations 
exist in patients with TSC1 or TSC2. Written informed consent was obtained for each 
clinical examination and DNA analysis per the IRB protocol. The informed consent 
included permission for a general physical examination and included an oral examination. 
Subjects were recruited from the Tuberous Sclerosis Center at Children's Hospital 
Medical Center, Cincinnati, Ohio, and all had a clinically definite diagnosis of tuberous 
sclerosis. There were no controls, and subjects were not randomized. 
ORAL EXAMINATIONS 
All oral examinations were completed in the Tuberous Sclerosis Center at 
Children' s Hospital Medical Center. A total of 104 exams were completed: 99 exams 
were completed by the author, and 5 exams were completed by a pediatric dental 
resident. Study subjects brushed their own teeth or had their teeth brushed to remove as 
much plaque as possible prior to staining the facial surfaces with Trace® disclosing 
solution (Red dye #28) using a 6-inch cotton swab. The teeth were examined using an 
explorer and a lighted mirror (DenLite® by WelchAllyn). Upon completion of the exam, 
patients again had their teeth brushed to remove the dye stain. As a standardized protocol 
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in data collection, an examination form was used (See Appendix II) to tabulate the 
following: 
1. The presence or absence of primary and permanent teeth. 
2. The total number and location of pits affecting the facial surfaces of the 
maxillary and mandibular incisors, canines, and first and second molars in the primary 
dentition were recorded. The total number and location of pits affecting the maxillary 
and mandibular incisors, canines, premolars, and frrst molars in the permanent dentition 
were recorded. 
3. Size of pits - Pits were categorized into one of two pit sizes and charted as 
follows: 
Pinpoint Size: The width of the tip of a dental explorer or smaller. 
Crater Size: The width greater than the tip of a dental explorer. 
4. Gingival fibromas- the total number and location of fibrous growths were 
recorded. 
TSC PHENOTYPE VARIABLES 
Patients participating in the study all had extensive testing, which included any or 
all of the following: MRl scans of the brain, echocardiography, renal ultrasound, an 
opthalmic examination, a neuropsychologic assessment, blood samples for genotype 
analysis, and an oral examination. As part of the larger IRE-approved study, one blood 
sample was obtained from each individual. Five to 10 ml of whole blood was obtained 
from individuals 1-1 0 years of age. Ten to 20 ml of blood was obtained from patients 
greater than 10 years of age. At no time did the total amount of blood removed from 
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each individual exceed 5 percent of their estimated total blood volume. All blood 
samples were obtained by the Test Referral Center at Children's Hospital Medical 
Center. Universal blood and body fluid precautions were followed. 
Confidentiality of a patient's identification was maintained. Genotype test results 
were not included in that patient's medical record; results were not divulged to any third 
party and were known only by investigators participating in the study. If individual 
subjects or family members desired the result of their genotype analysis, this was ve~bally 
communicated to them by the Division of Human Genetics at Children's Hospital 
Medical Center. Results of the genotype analysis were correlated with the phenotype of 
particular individuals only for the purpose of statistical analysis and to ascertain whether 
certain oral manifestations are associated with certain genetic mutations. 
METHOD OF DNA EXTRACTION 
DNA was extracted from leukocytes using a technique of isolation by differential 
affinity at Children's Hospital Medical Center. QIAamp DNA Blood Kits (QIAGEN®) 
for large-scale genomic and viral DNA purification was used to isolate pure DNA ready 
for amplification. Using this system, separation of leukocytes from whole blood was not 
necessary. The procedure consisted of the following steps: 
1. Five-1 0 ml of blood was added to a 50 Jll centrifuge tube. 
2. Five hundred Jll of QIAGEN Protease stock solution and 12 ml of Buffer AL 
was added and mixed thoroughly by vortexing. 
3. Mixture was incubated at 70 oc for 10 minutes. 
4. Ten Jll of ethanol was added to the sample and mixed by vortexing. 
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5. Half of the solution was applied onto the QIAamp Maxi column and placed in 
a 50-ml centrifugation tube and centrifuged at 3000 rpm for 3 minutes. 
6. The QIAamp Maxi column was removed, the filtrate discarded, and the Maxi 
column was placed back into the 50-ml centrifugation tube. The remaining half of the 
solution was applied onto the QIA Maxi column, placed in the centrifugation tube and 
centrifuged at 3000 rpm for 3 minutes. 
7. The QIA Maxi column was removed, the filtrate discarded, and the column 
placed back into the centrifugation tube. 
8. Five ml of Buffer A W1 was added to the Maxi column and was centrifuged at 
5000 rpm for 1 minute. 
9. Five ml of Buffer A W2 was added to the Maxi column and centrifuged at 5000 
rpm for 15 minutes. 
10. The Maxi column was removed and placed in a clean 50 ml centrifugation 
tube, and 1 ml ofBuffer Acetate EDTA was added onto the membrane of the column, 
incubated at room temperature for 5 minutes, and centrifuged at 5000 rpm for 5 minutes. 
11. A 1:100 dilution of the sample was then placed in a Beckman 
Spectrophotometer to evaluate the yield. 
METHOD OF DNA MUTATION ANALYSIS 
Once an adequate yield was confrrmed, samples were sent to Brigham and 
Women's Hospital in Boston, Mass. for analysis for mutations of either of the tuberous 
sclerosis genes by David Kwiatkowski, M.D., Ph.D. These results were then 
communicated to the investigators at CHMC and made available for the dental study. 
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Denaturing high performance liquid chromatography (DHPLC) was used for exon 
by exon mutation detection of point mutations and small insertions/deletions in TSC 1 and 
TSC2 genes. This was followed by a long-range PCR assay for identification of large 
deletions in TSC2. DHPLC is a recently developed method for DNA variation detection 
that uses reversed phase ion pair liquid chromatography to detect DNA 
heteroduplexes.62'68-70 Its advantages over other methods of DNA analysis include 
superiority in detection of DNA sequence variation as well as its semi-automation. Up to 
96-well tray samples can be loaded on the apparatus at one time and subject to analysis 
over several hours. The process involved the following steps: 
1. The DNA sample was diluted 1:20 and gel electrophoresis was run on a 0. 7 
percent agarose gel to verify DNA presence. 
2. Samples were then subjected to a PCR reaction for amplification of exons 
using a PTC-1 00 thermal cycler with primers and buffers. Primer sequences for PCR 
amplification ofTSC2 exons can be found at http://zk.bwh.harvard.edu/projects/tsc/. The 
DNA was denatured to single strands by adding EDT A to the sample and heating to 
95 °C for 5 minutes. Reannealing to form heteroduplexes products occurred after 1 hour 
at 65 °C. 
3. Heteroduplexes were analyzed using the DHPLC WAVE TM DNA Fragment 
Analysis System (Transgenomic, Inc., San Jose, CA). 
4. Chromatograms were established for each DNA fragment amplicon and were 
compared with controls to detect samples with probable mutations. 
5. Sequence variation was identified by loading the samples onto an ABI gel for 
automated sequencing using an ABI 377 machine (Perkin-Elmer). Sequencing was bi-
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directional along with controls to minimize errors. The data from the ABI chromatogram 
was transferred to a computer with software capable of detecting mutations. 
6. Samples were screened for large TSC2 deletions using long-range PCR 
methods that use a series of PCR primers and agarose gel electrophoresis. Long PCR-
based assay utilizes primers that amplify overlapping segments of the TSC2 gene to 
increase the probability of finding all deletions. 
TABULATION OF DATA 
Results of the neuro-imaging, neuropsychological, renal imaging, 
echocardiogram, TSC mutations, and oral fmdings were entered into a database created in 
Microsoft Access® for tabulation purposes (See Tables I, II and III). Variables for 
phenotype correlations included a history of polycystic kidney disease (PKD), cardiac 
rhabdomyomas, arrhythmias, facial angiofibromas, renal angiomyolipomas, and retinal 
disturbances. Correlations were also made to the total number of cortical tubers, the 
degree of cognitive impairment, seizure severity, and the total number of anti epileptic 
drugs required to control seizures (AEDs). 
MUTATION GROUPING 
Due to the limited number of TSC 1 patients, mutation analysis was limited to 
TSC2 patients. Mutations were grouped as either resulting in truncating mutations 
leading to premature termination of the protein or as non truncating mutations resulting in 
an altered protein. Truncating mutations included small deletions or insertions, nonsense, 
splice site, frameshift mutations. Large genomic deletions that result in no protein 
30 
product were also included in this category, because the effect is essentially the same as 
truncation. The nontruncating category included missense mutations and in-frame 
deletions. 
STATISTICAL METHODS 
To compare means of oral findings and angiomyolipomas (AML) polycystic 
kidney disease (PKD), cardiac rhabdomyomas, cardiac arrhythmias, facial angiofibromas, 
retinal lesions, seizure activity, familial vs sporadic disease, and mutation categories, the 
two sample t-test was used. The one-factor analysis of variance (ANOVA) was employed 
to evaluate oral fmdings against seizure severity and the degree of cognitive impairment 
where the number of groups was more than two. If the results from ANOVA were 
statistically significant, the Bonferroni adjustment factor was applied to determine which 
pairwise groups had different means. The chi-square was used to test for differences in 
proportions in examining the appearance of oral fibromas with AML, PKD, cardiac 
rhabdomyomas, cardiac arrhythmias, facial angiofibromas and retinal fibromas. 
Pearson's correlation coefficient was computed for pairs of quantitative phenotype 
variables. Spearman's rho was used to examine the relation between oral findings and 
categories of phenotype variables. 
SAS Version 7.0 was used forT-tests, ANOVA, and chi-square analyses, while 
SPSS version 9.0 was used for correlation analyses. 
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RESULTS 
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ORAL FINDINGS 
Enamel Pitting 
A total of 1 04 patients with a clinical diagnosis of tuberous sclerosis were 
examined for enamel pitting and gingival fibromas over a two-year period from 5/13/98 
to 6/7/00. A total of 46 males (44 percent) and 58 females (56 percent) were included in 
the study. Of the total, 31 patients (30 percent) were in the primary dentition, 19 patients 
(18 percent) in the mixed dentition and 54 patients (52 percent) in the permanent 
dentition. The age range of patients examined was from 1 year to 51 years of age. These 
data are shown in Tables I part I-V and summarized in Figure 4. 
Collectively, the study subjects had a total of2223 teeth examined. Of the 1487 
permanent teeth examined, 604 (41 percent) had enamel pitting with 83 percent of the 
pitting classified as pinpoint-sized pits, and 17 percent as crater-sized pits. Seven 
hundred and thirty-six primary teeth were examined of which 53 (6 percent) displayed 
pitting, with 91 percent of the pitting classified as pinpoint, and 9 percent as craters sized 
pits. These data are summarized in Figures 6 and 7. 
Twenty-nine percent of the patients in the primary dentition group had enamel 
pitting with an average of 2.2 pits per affected patient with a maximum of 4 pits per 
individual patient. Ninety percent of those in the mixed dentition group had enamel 
pitting with an average of 10.8 pits per affected patient and a maximum of 41 pits per 
individual patient. One hundred percent of patients in the permanent dentition group had 
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enamel pitting with an average of 16.4 pits per individual and a maximum of 68 pits per 
individual patient. These data are summarized in Figures 5, 7, and 14 
Over 60 percent of enamel pitting occurred in the maxillary arch for both primary 
and permanent teeth with the majority of enamel pitting occuring anteriorly for both sets 
of teeth (see Figures 8 and 9). The maxillary canine was the most common primary tooth 
affected, with a pitting occurrence of24 percent (see Figure 11) and also displayed the 
greatest number of enamel pits of all primary teeth with an average of 0.26 pits (see 
Figure 12). The average number of enamel pits for all primary teeth was 0.07. The 
maxillary central incisor was the most common permanent tooth affected, with a pitting 
occurrence of 78 percent (see Figure 1 0) and displayed the greatest number of pits of all 
permanent teeth with an average of 1.42 pits. (see Figure 13). The average number of 
enamel pits for all permanent teeth was 0. 70 pits. 
Gingival Fibromas 
Gingival fibromas were seen in 4 7 percent of patients between 6 and 13 years of 
age, and in 70 percent of patients in the permanent dentition (see Figure 15). Only one 
patient under the age of six years old had a gingival fibroma. It was located anteriorly in 
the maxillary arch. The majority of gingival fibromas occurred in the maxillary arch (62 
percent) and occurred anteriorly positioned (72 percent for patients in the mixed dentition 
and 77 percent for patients in the permanent dentition). These data are shown in Table X, 
Parts I-V and summarized in Figures 16 and 17. 
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The fibromas were primarily fibrous nodules covered with mucosa of normal 
color and located more often on the interdental papilla of the facial gingiva (see Figure 
3). They varied from a few millimeters to 1 em in size and all were asymptomatic. 
The average number of gingival fibromas per affected patient was 6.4 for patients 
in the mixed dentition group, and 4.8 for patients in the permanent dentition group. A 
two-sample test failed to show a significant difference between the two means. 
COMPARING ENAMEL PITTING TO 
PHENOTYPE VARIABLES 
Phenotype Variables With a Lack of Significant Findings 
Using T-tests and Spearman's rho correlation analyses, there were no significant 
findings between the degree or severity of enamel pitting in the primary or permanent 
teeth with AML, PKD, cardiac rhabdomyomas and hypertension and retinal lesions. 
These data are shown in Tables II, V, VI, VII, X and XV-Parts I and II and summarized 
in Table XVIII-Parts I, II and III. 
T-tests did not show significant differences in the degree or severity of enamel 
pitting in either the primary or permanent teeth in patients with and without seizures. 
Likewise, the ANOVA for seizure severity failed to show significant differences with 
enamel pitting. Additionally, there were no correlations between the degree or severity 
of enamel pitting in either dentition and the total number of anti-epileptic drugs (AEDs) 
taken to control seizures. These data are shown in Tables XI, XV-Part I and XVI and 
summarized in Table XVIII-Part I. 
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The level of cognitive impairment was described as unaffected, mild, moderate or 
severe. Analyses of variance failed to show any significant differences between the level 
of impairment and degree or severity of enamel pitting in the primary or permanent teeth. 
These data are shown in Table XVI and summarized in Table XVIII-Part I. 
Cardiac Arrhythmias and Facial Angiofibromas 
There was a positive correlation between cardiac arrhythmias and the average 
number of enamel pits in primary teeth (r = 0.408; 12. = 0.0 14; n = 36) but not in 
permanent teeth; however, the t-test analyses between the two groups failed to show a 
significant difference. There was no correlation between the severity of pitting with 
cardiac arrhythmias. These data are shown in Tables II, VIII and XV -Part I and 
summarized in Table XVIII-Part II. 
There was a positive correlation between the average number of pits in the 
primary (r = 0.527; 12. = 0.002; n = 32) as well as permanent (r = 0.378; 12. = 0.011; 
n = 44) teeth with the presence of facial angiofibromas. The t-test for both primary 
(1 =- 2.76; 12. = 0.009) and permanent (1 = -2.62; 12. = 0.012) teeth revealed a significant 
difference between the means. There was no correlation between severity of pitting with 
facial angiofibromas. These data are shown in Table IX and XV-Part II and summarized 
in Table XVIII-Part III. 
Total Number of Cortical Tubers and IQ Estimation 
IQ estimates were completed by a neuropsychologist and were based on actual 
test results (i.e. Bayley Scales of Infant Development, Wechsler Intelligence Scale for 
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Children, 3rd edition). Otherwise, IQ estimates were based on school and job 
performance and clinical judgments of disease severity. There was a negative correlation 
between the average number of enamel pitting in the primary teeth and estimation ofiQ 
(r = -0.405; p = 0.05; n = 24). 
Tuber count was determined by a radiologist from MRI imaging. Given the large 
number of tubers in most of the patients, a maximum of 10 tubers were counted in each 
of four examined areas. Patients with more than 10 tubers were assigned a count of 11 
for the purposes of quantitative analysis. The maximum number of tubers in the scoring 
system was 44. There was a negative correlation between the percent of crater-sized pits 
in the permanent teeth and the total number of cortical tubers (r = -0.587; p = 0.035; 
n = 13). There was a positive correlation, however, between the percent of pinpoint-
sized pits in permanent teeth and total number of cortical tubers ( r = 0.587; p = 0.035; 
n = 13). These data are shown in Table XV (Part I) and summarized in Table XVIII 
(Part I). 
COMPARING ENAMEL PITTING WITH TSC GENETICS 
Familial vs. Sporadic Disease 
There were no significant associations between the number and degree or severity 
of enamel pitting in the primary or permanent teeth with familial cases compared with 
sporadic cases of tuberous sclerosis. These data are shown in Tables III, XII and XV 
(Part III), and summarized in Table XIX. 
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Truncating vs. Nontruncating Mutations 
There were no significant associations between the degree and severity of enamel 
pitting in the primary and permanent teeth with TSC2 mutations leading to truncated as 
compared with nontruncated protein products. These data are shown in Tables III, XIII 
and XV (Part III), and are summarized in Table XIX. 
COMPARING GINGIVAL FIBROMAS 
WITH PHENOTYPE VARIABLES 
Phenotype Variables Lacking Significant Findings 
Using statistical tests consisting oft-tests, ANOV A, Pearson's correlation, 
Spearman's rho, and chi-square used separately or in combination, there were no 
significant findings between the number of gingival fibromas either anteriorly or 
posteriorly positioned with these phenotype variables. The data are shown in Tables V, 
VI, VII, X, XI, XII, XIII, XIV, XV (Parts I and II), XVI, and are summarized in Table 
XVIII (Parts I, II, and III). 
Retinal Lesions 
There was positive correlation between the total number of gingival fibromas and 
the appearance of retinal lesions (r = 0.372; p = 0.020; n = 39). The frequency of patients 
with gingival fibromas increased proportionally with retinal lesions [X2 (1) = 4.96; 12 = 
0.0258]. T-tests failed to show a difference between patients with and without gingival 
fibromas and retinal lesions. These data are shown in tables X, XIV, XV (Part II) and are 
summarized in Table XVIII (Part III). 
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Cardiac Arrhythmias 
There were significant differences between the total number of gingival fibromas 
(1 = 2.65; n = 0.01), both anteriorly (1 = 2.31; n = 0.02) and posteriorly (1 = 2.18; 
n = 0.03) positioned with the occurrence of cardiac arrhythmias. The Chi-square test did 
not show significance and correlation analyses failed to demonstrate a correlation. These 
data are shown in Tables VIII, XIV and XV (Part I) and are summarized in Table XVIII 
(Part II). 
Facial Angiofibromas 
There was a positive correlation between the total number of gingival fibromas 
and the occurrence of facial angiofibromas (r = 0.514; p < 0.0001; n = 64). There was a 
significant difference in the average number of gingival fibromas in patients with facial 
angiofibromas (t = -3.32; p = 0.0015) compared to those without, and the frequency of 
gingival fibromas increased in proportion with facial angiofibromas [X (1) = 18.95; n 
<0.0001]. These data are shown in Tables IX, XIV, and XV (Part II) and are summarized 
in Table XVIII (Part III). 
COMPARING GINGIVAL FIBROMAS 
WITH TSC GENETICS 
Familial vs. Sporadic Disease 
There were no significant associations between the total number of gingival 
fibromas, either anteriorly or posteriorly positioned in patients with familial or sporadic 
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TSC. These data are shown in Tables XII and XV (Part III) and are summarized in Table 
XIX. 
Truncating vs. Nontruncating Mutations 
There were no significant associations between the total number of gingival 
fibromas, either anteriorly or posteriorly positioned, and TSC2 mutations leading to 
truncated or nontruncated protein products. These data are shown in Tables XIII and XV 
(Part III) and summarized in Table XIX. 
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FIGURE 1. Facial angiofibromas characteristic of 
Tuberous Sclerosis Complex 
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FIGURE 2. Enamel pitting. Pinpoint size enamel pitting 
(A) and crater size enamel pitting (B) characteristic 
of tuberous sclerosis complex. Red dye has become 
entrapped in the pits enhancing their recognition. 
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FIGURE 3. A gingival fibroma in a patient with 
Tuberous Sclerosis Complex 
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FIGURE 4. Total number of patients examined with a clinical diagnosis of 
Tuberous Sclerosis Complex (TSC) by gender, age and dentition. 
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FIGURE 5. Occurrence of enamel pitting in patients in the primary, mixed and 
permanent dentitions. 
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FIGURE 6. Total number of primary and permanent teeth examined 
affected by enamel pitting. 
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FIGURE 7. Distribution of pinpoint vs. crater size enamel pitting 
affecting primary and permanent teeth examined. 
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FIGURE 8. Occurrence of enamel pitting affecting maxillary and mandibular arches 
in primary and permanent teeth examined. 
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FIGURE 9. Occurrence of enamel pitting affecting anterior and posterior arch 
positions in primary and permanent teeth examined. 
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FIGURE 10. Permanent teeth affected by enamel pitting (percentage by tooth). 
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FIGURE 11. Primary teeth affected by enamel pitting (percentage by tooth). 
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FIGURE 13. Average number of enamel pits per permanent tooth examined. 
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FIGURE 14. Average number of enamel pits per affected patient in the primary, mixed, 
and permanent dentitions. 
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FIGURE 15. Percent of patients examined with gingival fibromas in the primary, 
mixed, and permanent dentitions. 
56 
Cl) 
ro 100 s 
0 90 ;._. 
...0 80 rz 
""@ 70 
.:::; 60 
bO 50 s::: 
C3 40 
Co+-c 30 0 
-+--> 20 s::: 
<1.) 10 (.) ;._. 
<1.) 0 ~ 
Mixed Permanent 
Dentition 
I QI Maxillay Mandibular I 
Dentition 
Fibromas 
Primary Mixed Permanent 
Maxillary 1 (100%) 36 (62%) 112 (62%) 
Mandibular 0 (0%) 22 (38%) 70 (38%) 
FIGURE 16. Occurrence of gingival fibromas affecting maxillary and mandibular 
arches in primary and permanent teeth examined. 
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FIGURE 17. Occurrence of gingival fibromas affecting anterior and posterior arch 
positions in patients in the primary, mixed, and permanent dentitions. 
7 -
6 
en 5 ro 
s 
0 4 1-c 
..0 
i:i: 3 ~ 0 
:::t:f: 2 1 
1 
0 I l I 
Primary 
# of Fibromas 
# of Patients with fibromas 
Maximum/patient 
Minimum/patient 
Standard Deviation 
T-Test 
N Mean 
Mixed Dentition 9 6.4 
Permanent Dentition 38 4.8 
58 
6.4 
."" 
Mixed 
Dentiti:m 
Primary 
1 
1 
1 
1 
NA 
t-value 
1.14 
4 .8 
Permanent 
Dentition 
Mixed Permanent 
58 182 
9 38 
14 19 
1 1 
5.47 4.22 
p-value Significant 
0.258 No 
FIGURE 18. Average number of gingival fibromas per affected patient in the primary, 
mixed, and permanent dentitons. T -tests compare the means for mixed and 
permanent dentitions. 
Table I- Part I 
Enamel pitting and gingival fibromas 
Age . Avg Pits/ Avg Pits/ 
MR# Date of Birth In Gender Dentition Primary %1P %1C Perm %2P %2C #AF #PF T#F 
years Tooth Tooth 
650558 1/811991 9 Male Mixed 1.78 100 0 2.27 76 24 0 0 0 
538938 8/27/1986 13 Male Mixed 0.5 100 0 0.78 92.85714 7.142857 10 3 13 
665678 11/1211990 9 Male Mixed 0 0.17 50 50 1 1 2 
735290 3/20/1991 9 Female Mixed 0 0.5 90.90909 9.090909 3 1 4 
653902 7/11/1989 10 Male Mixed 0 0.08 100 0 0 0 0 
747840 2/28/1994 6 Female Mixed 0.16 100 0 0 0 0 0 
947789 12/30/1989 10 Male Mixed 0 0 0 0 0 
648043 5/17/1990 9 Female Mixed 0 0.64 100 0 0 0 0 
590073 5/9/1985 13 Female Mixed 1 0 100 1.04 76 24 0 0 0 
643642 5/14/1990 8 Male Mixed 0.42 60 40 0 0 0 0 
707496 6/2311990 10 Male Mixed 0 0.42 80 20 4 3 7 
881133 2/1211991 9 Male Mixed 0 0.91 80 20 0 0 0 
956684 8/2711990 9 Male Mixed 0 0.38 100 0 0 0 0 
667200 7/25/1990 9 Male Mixed 0.25 100 0 0 11 3 14 
754477 711411988 11 Male Mixed 0 0.25 100 0 1 0 1 
651624 12/29/1990 9 Female Mixed 0.17 100 0 1.5 91.66667 8.333333 1 2 3 
100134 12/8/1992 7 Male Mixed 0 0 0 0 0 
538939 8/27/1986 13 Male Mixed 0.5 100 0 0.78 92.85714 7.142857 10 3 13 
825131 7/27/1991 8 Male Mixed 0.5 100 0 0.5 50 50 1 0 1 
870212 2/411962 38 Female Permanent 0.54 100 0 10 4 14 
766005 6/4/1969 31 Female Permanent 0.95 90.47619 9.52381 3 2 5 
100222 11/2511964 36 Female Pem1anent 0.21 100 0 1 0 1 
819249 6/17/1986 14 Female Permanent 1.63 97.4359 2.564103 2 0 2 
913045 4/14/1974 26 Female Permanent 0.68 86.66667 13.33333 1 0 1 
999999 12/20/1973 25 Female Permanent 0.46 63.63636 36.36364 10 9 19 
(continued) 
Age 
MR# Date of Birth In Gender 
years 
367616 8/13/1980 19 Male 
576477 7/13/1988 11 Male 
999998 12/2/1955 43 Female 
1003601 517/1957 43 Female 
425507 2/6/1979 20 Male 
100133 10/22/1964 35 Female 
748578 3/4/1985 15 Female 
100100 5/7/1971 29 Male 
885963 4/27/1965 34 Female 
955338 5/24/1983 16 Male 
345963 3/23/1979 21 Male 
901893 9/28/1965 33 Female 
258704 4/23/1974 26 Female 
955348 1/9/1982 18 Male 
100110 9/29/1964 35 Female 
787714 1/1811978 22 Male 
956892 2/24/1976 24 Female 
553907 7/29/1987 12 Female 
976346 11119/1968 31 Male 
385891 9116/1980 19 Female 
100006 12/21/1962 37 Female 
222222 8/28/1981 18 Female 
936854 12/2/1955 44 Female 
447887 8/25/1982 18 Female 
100200 3115/1960 40 Female 
Table I- Pati II 
Enamel pitting and gingival fibromas 
- Avg Pits/ Avg Pits/ 
Dentition Primary %1P %1C Perm %2P 
Tooth Tooth 
Permanent 0.79 100 
Permanent 0.13 100 
Permanent 0.35 100 
Permanent 0.13 100 
Permanent 0.71 70.58824 
Permanent 0.88 76.19048 
Permanent 1.09 70.83333 
Permanent 0.96 69.56522 
Permanent 1.41 100 
Permanent 0.21 100 
Permanent 0.46 81.81818 
Permanent 1.35 48.3871 
Permanent 0.88 71.42857 
Permanent 1.42 82.35294 
Permanent 1.77 100 
Permanent 0.75 94.44444 
Permanent 0.75 72.22222 
Permanent 0.63 80 
Permanent 0.79 63.15789 
Permanent 0.42 100 
Permanent 0.35 100 
Permanent 0.25 100 
Permanent 0.25 80 
Permanent 0.13 66.66667 
Permane(nt 0.08 100 
(continued) 
%2C #AF 
0 0 
0 2 
0 1 
0 2 
29.41176 4 
23.80952 2 
29.16667 1 
30.43478 7 
0 1 
0 8 
18.18182 2 
51.6129 3 
28.57143 4 
17.64706 7 
0 6 
5.555556 3 
27.77778 4 
20 5 
36.84211 2 
0 14 
0 0 
0 9 
20 1 
33.33333 0 
0 2 
#PF 
0 
0 
0 
2 
0 
0 
0 
1 
3 
0 
0 
0 
1 
2 
0 
0 
1 
0 
0 
0 
0 
2 
1 
1 
1 
T#F 
0 
2 
1 
4 
4 
2 
1 
8 
4 
8 
2 
3 
5 
9 
6 
3 
5 
5 
2 
14 
0 
11 
2 
1 
3 
0\ 
0 
Table I- Part III 
Enamel pitting and gingival fibromas 
Age - Avg Pits/ Avg Pits/ 
MR# Date of Birth In Gender Dentition Primary %1P %1C Perm %2P %2C #AF #PF T#F 
years Tooth Tooth 
100005 12/25/1955 44 Female Permanent 0.6 75 25 0 2 2 
886514 12/12/1986 13 Male Permanent 0.08 50 50 0 0 0 
738440 7/6/1987 12 Male Permanent 0.75 88.88889 11.11111 1 0 1 
300635 5/16/1970 30 Female Permanent 0.46 81.81818 18.18182 0 0 0 
260096 2/3/1974 26 Male Permanent 0.42 90 10 5 2 7 
100130 1/22/1949 51 Female Permanent 1 87.5 12.5 0 0 0 
251743 10/28/1969 31 Male Permanent 2.83 79.41176 20.58824 3 0 3 
604607 6/15/1988 12 Female Permanent 0.17 100 0 0 0 0 
968031 5/28/1988 12 Male Permanent 0.71 88.23529 11.76471 0 0 0 
825130 5/16/1984 16 Female Permanent 1.33 84.375 15.625 0 0 0 
100002 2/28/1967 33 Female Permanent 0.17 100 0 0 0 0 
535368 3/25/1986 13 Female Permanent 1.46 100 0 0 0 
751954 6/111987 12 Female Permanent 0.08 100 0 0 0 0 
279367 7/2211973 26 Female Permanent 0.17 75 25 0 2 2 
937450 7/17/1981 19 Male Permanent 0.92 90.90909 9.090909 0 2 2 
542204 7/15/1988 12 Female Permanent 0.17 75 25 1 0 1 
100003 8/2111968 31 Male Permanent 0.08 100 0 0 0 0 
100004 1/7/1983 17 Female Permanent 0.46 100 0 0 0 0 
100101 2/5/1973 22 Female Permanent 0.42 70 30 0 0 0 
442009 10/7/1982 17 Female Permanent 1.46 91.42857 8.571429 0 0 0 
187859 2/26/1968 32 Female Pem1anent 1.88 42.22222 57.77778 3 0 3 
952798 12/28/1979 20 Female Permanent 0.75 72.22222 27.77778 0 0 0 
770763 911/1994 6 Female Primary 0.1 100 0 1 0 1 
816446 8/611994 6 Male Primary 0 0 0 0 
968603 3/14/1998 2 Female Primary 0 0 0 0 
(continued) 
Table I - Part IV 
Enamel pitting and gingival fibromas 
Age - Avg Pits/ Avg Pits/ 
MR# Date of Birth In Gender Dentition Primary %1P %1C Perm %2P %2C #AF #PF T#F 
years Tooth Tooth 
980596 8116/1995 5 Female Primary 0 0 0 0 
926965 2/24/1998 2 Female Primary 0 0 0 0 
830937 6/2411996 4 Male Primary 0 0 0 0 
871701 9/28/1997 2 Male Primary 0 0 0 0 
898884 10/30/1997 3 Female Primary 0.2 100 0 0 0 0 
971486 1/25/1995 5 Male Primary 0 0 0 0 
976334 12/19/1998 1 Male Primary 0.06 0 100 0 0 0 
963382 6/911993 7 Female Primary 0 0 0 0 
797818 9/11/1995 4 Female Primary 0 0 0 0 
798003 7/11/1995 4 Female Primary 0 0 0 0 
100001 4/16/1996 3 Female Primary 0 0 0 0 
853946 4/8/1997 3 Male Primary 0 0 0 0 
748228 2/28/1994 5 Male Primary 0.1 100 0 0 0 0 
808288 12/28/1995 4 Male Primary 0 0 0 0 
760824 5/13/1993 6 Male Primary 0 0 0 0 
768864 10/29/1994 5 Female Primary 0 0 0 0 
956669 9/25/1997 2 Female Primary 0 0 0 0 
919291 5/22/1998 2 Male Primary 0 0 0 0 
819241 12/25/1995 3 Female Primary 0.1 100 0 0 0 0 
889314 8/9/1996 3 Male Primary 0 0 0 0 
896539 6/1/1998 1 Female Primary 0 0 0 0 
735516 6/12/1993 5 Female Primary 0.2 75 25 0 0 0 
749246 2/24/1993 6 Female Primary 0.1 100 0 0 0 0 
781670 1/19/1994 4 Male Primary 0.05 100 0 0 0 0 
882846 3/1511997 1 Male Primary 0 0 0 0 
( conitnued) 
Table I- Part V 
Enamel pitting and gingival fibromas 
Age - Avg Pits/ Avg Pits/ 
MR# Date of Birth In Gender Dentition Primary %1P %1C Perm %2P %2C #AF #PF T#F 
years Tooth Tooth 
924171 9/2911997 2 Male Primary 0.1 100 0 0 0 0 
958384 4/22/1998 2 Male Primary 0 0 0 0 
855110 1/27/1997 2 Male Primary 0 0 0 0 
TABLE II - Part I 
~henotype Variables 
MR# PKD Hyperten- Cardiac Ash Angio- Cognitive #of #of Arrhyth- AML Retinal Seizure 
SlOll Leaf fibromas Impairment Tubers AEDs m1as Sx Severity 
used 
768864 No No No Yes No Moderate 7 No No No Intractable 
898884 Moderate 0 0 Controllable 
936854 Unaffected Controllable 
999998 Mild 
576477 No No No Yes Yes Mild 12 1 No Yes Yes Controllable 
367616 No No No Yes Yes Moderate 7 3 No No Controllable 
667200 No No Yes Yes Yes Severe 23 3 No No Controllable 
797818 No No Yes Yes Yes Mild 13 2 Yes No Yes Controllable 
648043 Yes No No Yes Yes Moderate 2 No Yes Controllable 
222222 No No Yes Unaffected 3 No No 
968031 No No Yes Severe 2 Yes Intractable 
279367 No No Yes Yes No Unaffected 0 No No No Controllable 
665678 No No No Yes No Moderate 2 No No No Controllable 
100222 Unaffected 0 0 No 
955338 Mild Controllable 
535368 No No No Yes Yes Unaffected 1 No No Controllable 
976334 Mild No 
871701 No No No Yes No Moderate 1 No No No Controllable 
956892 Yes Yes Mild Yes Controllable 
748578 No No Yes Yes Yes Severe 13 5 No Yes No Controllable 
913045 No No Yes Yes Moderate 14 5 Yes Controllable 
955348 Unaffected No 
(continued) 
TABLE II- Part II 
~henotype Variables 
MR# PKD Hyperten- Cardiac Ash Angio- Cognitive #of #of Arrhyth- AML Retinal Seizure 
sion Leaf fibromas Impairment Tubers AEDs m1as Sx Severity 
used 
825131 No No No Yes Yes Severe 0 Yes Yes Contra llab le 
819241 Yes No No Yes No Severe 11 0 No No No Intractable 
870212 Yes No No Yes Yes Severe 0 No Yes No Intractable 
760824 No No No Yes Yes Severe 22 0 No No No Contra llab le 
604607 Unaffected Controllable 
825130 No No Yes Yes Yes Unaffected 0 No No No 
754477 Yes Yes Yes Yes Yes Moderate 1 No Yes Yes Controllable 
251743 Severe 0 0 Controllable 
819249 No No Yes Yes Severe 0 Yes Intractable 
735516 No No Yes Yes Yes Mild 0 Yes No No Controllable 
590073 No No Yes Yes Yes Moderate 0 No No No Contra llab le 
385891 No No No Yes Yes Mild 0 No No No Controllable 
952798 Controllable 
937450 No Yes Yes No Unaffected 0 Yes Yes No 
100005 Unaffected No 
447887 No No No Yes Yes Unaffected 8 No No No Controllable 
963382 Severe Intractable 
971486 Unaffected No 
100110 Unaffected Controllable 
924171 No No Severe 4 No Intractable 
968603 Yes No Yes Yes No Mild 4 No No Intractable 
553907 No No No Yes Moderate 16 1 No No Controllable 
(continued) 
MR# PKD Hyperten- Cardiac Ash 
sion Leaf 
748228 No No Yes Yes 
100001 No No No Yes 
100003 
100002 
100200 
643642 Yes No Yes Yes 
751954 No No No Yes 
881133 No No No Yes 
886514 
980596 
919291 No No Yes Yes 
830937 No No No Yes 
300635 No No Yes 
855110 No Yes 
651624 No No Yes 
653902 No No No Yes 
538938 No No No Yes 
538939 No No No Yes 
976346 
442009 Yes No No Yes 
882846 No No Yes Yes 
100006 
TABLE II- Part III 
~henotype Variables 
Angio- Cognitive #of 
fibromas Impairment Tubers 
No Severe 11 
No Mild 
Unaffected 
Unaffected 
Unaffected 
No Unaffected 
Yes Moderate 22 
Yes Moderate 
Unaffected 
Mild 
No Unaffected 
No Unaffected 
Yes Unaffected 
No Unaffected 
Yes Mild 16 
No Unaffected 
Yes Unaffected 19 
Yes Unaffected 19 
Moderate 
Yes Severe 
No Mild 
Unaffected 
(continued) 
#of Arrhyth-
AEDs m1as 
used 
0 Yes 
No 
0 No 
0 No 
0 No 
0 No 
0 No 
0 
0 No 
0 No 
3 No 
0 No 
0 No 
0 No 
1 No 
AML Retinal 
Sx 
Yes No 
No No 
Yes 
Yes No 
Yes No 
No 
No No 
Yes 
Yes 
Yes 
No 
No 
Yes No 
No No 
Seizure 
Severity 
Controllable 
Controllable 
No 
No 
Controllable 
No 
Controllable 
Controllable 
Controllable 
Controllable 
Controllable 
Controllable 
Controllable 
Controllable 
Controllable 
Controllable 
No 
No 
Controllable 
Controllable 
Intractable 
No 
0\ 
0\ 
TABLE II- Part IV 
~henotype Variables 
MR# PKD Hyperten- Cardiac Ash Angio- Cognitive #of #of Arrhyth- AML Retinal Seizure 
SlOn Leaf fibromas Impairment Tubers AEDs m1as Sx Severity 
used 
816446 Yes Unaffected 0 No 
103601 Unaffected Controllable 
650558 Yes No Yes Yes Moderate 11 3 Yes Yes No Controllable 
542204 No No Yes Yes Yes Moderate 3 0 No Yes No Controllable 
889314 No Yes Yes No Unaffected 0 No No Controllable 
425507 Yes No Yes Yes Yes Moderate 13 0 Yes No No Controllable 
956669 No No No Yes Mild No No Intractable 
787714 Yes No Yes Yes Yes Moderate 0 No No No Intractable 
100004 No 
901893 No No Yes Yes Unaffected 0 Yes Yes No No 
345963 Yes No No Yes Yes Moderate 0 Yes Yes Controllable 
766005 No No No Yes Yes Moderate 2 4 No No No Controllable 
707496 Severe Intractable 
258704 No No Yes Mild 0 No Yes No 
187859 No No Yes Yes Yes Severe 0 No No Yes Intractable 
747840 Yes No Yes Yes Yes Unaffected 0 Yes No Controllable 
749246 No No Yes Yes No Unaffected 15 0 Yes No No No 
100133 No No Yes Mild Yes Controllable 
100134 No No Yes Yes No Moderate 16 0 No Yes Intractable 
798003 No No No Yes No Mild 0 No No No Controllable 
738440 Yes No No Yes Yes Moderate 22 0 No Yes Controllable 
735290 No No Yes Yes Yes Mild 0 .No No Yes Controllable 
(continued) 
MR# PKD Hyperten- Cardiac Ash 
SlOll Leaf 
260096 
958384 
956684 
926965 No No No Yes 
999999 No Yes Yes Yes 
100100 No No Yes 
808288 
947789 No Yes Yes 
896539 No Yes Yes 
853946 No Yes Yes 
885963 Yes No Yes Yes 
770763 No No Yes Yes 
TABLE II - Part V 
:rhenotype Variables 
Angio- Cognitive #of #of 
fibromas Impairment Tubers AEDs 
used 
Severe 
Unaffected 
Unaffected 
No Unaffected 0 
Yes Unaffected 0 
Yes Unaffected 2 
Moderate 0 
Moderate 
No Moderate 0 
No Unaffected 0 
Yes Unaffected 0 
Yes Unaffected 0 0 
Arrhyth- AML 
m1as 
No No 
No Yes 
No Yes 
Yes Yes 
No 
No 
No Yes 
No No 
Retinal 
Sx 
Yes 
No 
No 
No 
Seizure 
Severity 
Controllable 
No 
No 
Controllable 
Controllable 
Controllable 
Controllable 
Controllable 
Controllable 
No 
Intractable 
No 
0\ 
00 
69 
TABLE III Part I 
Mutation/Familial vs Sporadic Disease 
MR# Familial/ Mutation Mutation Mutation 
Sporadic Type Catego~y 
650558 Familial 
538938 Familial 2:E 33.2 4432G>C D1478H-1 Missense Nontruncating 
735290 Sporadic 2:del4.5 Kb Missense Nontruncating 
653902 Familial 2:E33 4271 A>G, 1424 :Q?G Missense Nontruncating 
648043 S_poradic 2:4681-1 G>A S_plice Truncating 
590073 Familial 2: 19, 465 kb deletion, Long PCR Large Deletion Truncating 
643642 Familial T1E4 342 C>A, L411 Missense Nontruncating 
881133 Sporadic 2:4843 del TGCT GGC Deletion Truncating 
667200 2:(E29)3411C>T,R1138X Nonsense Truncati~g 
100134 Familial 2:5042 C>T, P 1675 L 
538939 Familial 2:E30 3750 C>G, Y1250X Nonsense Truncating 
82513 1 Sporadic 2:E9 911G>A, W304X Nonsense Truncating 
870212 S_poradic 2:E39 5126 C>T,P1709L-3 Missense Nontruncating 
819249 no mutation no mutation 
913045 S_poradic 2:E16 1832 G>A, R611Q Missense . Nontruncati~g 
999999 Familial 2:18 2098-1 G>A Splice Truncati~g 
367616 Familial 2:E2~, 3212 del A Frameshift Trunc~ting 
425507 1:14, 432-1 G>A* Splice Truncating 
100133 Familial 2:5042 C>T, P 1675 L Missense Nontruncating 
748578 2:792+ 1 2T>A Splice Truncating 
100100 Familial 2:18 2098-1 G>A Splice Truncating 
885963 Familial 2:E32 3985 Ins G Frameshift Truncating 
901893 Familial 2:E41, 5276 C>A,A17759 D-2 Missense Nontruncating 
100110 . Familial 
95689'2 . 2:E9, 903-922 del Deletion Truncating 
385891 Familial 1 :E19 2713 ins A Frameshift 
Truncating 
100006 Familial 
936854 Sporadic 
447887 E12 1318 G>A, 440G>S Missense 
Nontruncating 
100200 Familial 
100005 Familial 1 :E15.1 1744 C>T, R582X Nonsense 
Truncating 
738440 2:E10 1094 3 pb del lose I&E_get K . Deletion 
Truncating 
300635 Familial 
260096 Sporadic 2:E29 3411 C>T, R1138X 
Nonsense Truncatiing 
279367 Familial 2:1795 A>G, H593R 
polymorphism Nontruncating 
937450 Familial 1 :E15.1 1744C>T,R582X 
Nonsense Truncating 
542204 s_poradic 2:E40 5205 C>G 1735 I>M 
Splice Truncating 
100004 Familial 
100101 Familial 
442009 2:885 ins C 
Splice Truncating 
187859 Familial E18 1960-61, del GG 
Deletion Truncating 
952798 Familial 1:E15.1 1744 C>T., R582X 
Nonsense Truncating 
770763 8_poradic 1 :E17 2355 5bp del CATCD- deletion 
Deletion Truncating 
816446 Familial 
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TABLE III Part II 
Mutation/Familial vs Sporadic Disease 
MR# Familial/ Mutation Mutation Mutation 
Sporadic Type Category 
968603 Sporadic 2:E38, 5075, del AGGG Deletion Truncating 
926965 Familial 2:118 2098-1 G>A Splice Truncating 
871701 Sporadic 1:1054 del CT Nonsense Truncating 
898884 Sporadic 
971486 Familial 
963382 Familial 
797818 2:E22 2639 +G>C Splice Truncating 
798003 Sporadic 2:209 del TGC Deletion Truncating 
100001 E17 1865 G>A, 622 R>Q Missense Nontruncating 
853946 Familial 
748228 Familial 2:E40 5228 G>A, R1743Q+ 1 Missense Nontruncating 
808288 2:E13 1372 C>T, R458X Nonsense Truncating 
760824 2:5270-77+ 1 I 9 del27 Frameshift Truncating 
768864 1:E8, 954C>T, R245X Nonsense Truncating 
919291 Familial 
819241 2:G3430 C>T, R1144X Nonsense Truncating 
896539 Sporadic 2:E37 4854del 1BP (C) Deletion Deletion Truncating 
735516 Familial 2:19, 465 kb deletion, Long PCR Large Deletion Truncating 
749246 Familial 
781670 2:1237 T>G, Y407D Nontruncating 
882846 Sporadic 2:990 C>G, Y324X Truncating 
855110 Familial 2:E118 2098-1 G>A Truncatin 
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TABLEV 
T-Test for angiomyolipomas (AML) and oral variables 
Variable N Mean t-value p-value Significant 
p < 0.05 
Primary Pitting N=25 0.122 -1.17 0.25 No 
Teeth Y=11 0.27 
Pinpoint N=11 88.63 -0.23 0.82 No 
Y=5 92 
Craters N=11 11.36 0.23 0.82 No 
Y=5 8 
Permanent Pitting N=19 0.67 -0.34 0.73 No 
Teeth Y=31 0.72 
Pinpoint N=17 82.72 -0.26 0.79 No 
Y=28 84 
Craters N=17 17.27 0.26 0.79 No 
Y=28 15.99 
Fibromas Total N=37 2.84 -0.25 0.80 No 
I Y=32 2.56 
Anterior N=37 2.08 0.10 0.92 No 
Y=32 2 
Posterior N=36 0.5 -0.96 0.34 No 
Y=32 0.84 
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TABLE VI 
T-Test for polycystic kidney disease (PKD) and oral variables 
Variable N Mean t-value p-value Significant 
p < 0.05 
Primary Pitting N=29 0.123 -1.58 0.123 No 
Teeth Y=7 0.35 
Pinpoint N=12 89.53 -0.3 0.97 No 
Y=4 90 
Craters N=12 10.41 0.03 0.97 No 
T=4 10 
Permanent Pitting N=34 0.657 -0.53 0.59 No 
Teeth Y=13 0.752 
Pinpoint N=31 82.748 -1.62 0.59 No 
Y=11 91.197 
Craters N=31 17.252 1.62 0.1 1 No 
Y=11 8.803 
Fibromas Total N=51 2.490 -0.28 0.78 No 
I Y=15 2.866 
Anterior N=51 1.862 -0.27 0.79 No 
Y=15 2.133 
Posterior N=50 0.64 -0.21 0.83 No 
N=15 0.733 
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TABLE VII 
T-Test for cardiac rhabdomyomas and oral variables 
Variable N Mean t-value p-value Significant 
p < 0.05 
Primary Pitting N=l7 0.0941 -0.86 0.39 No 
Teeth Y=22 0.189 
Pinpoint N=4 100 0.99 0.34 No 
Y=10 83.5 
Craters N=4 0 -0.99 0.34 No 
Y=10 16.5 
Permanent Pitting N=23 0.669 -0.08 0.93 No 
Teeth Y=20 0.683 
Pinpoint N=23 84.97 0.92 0.36 No 
Y=15 79.87 
Craters N=23 15.027 -0.92 0.36 No 
Y=15 20.123 
Fibromas Total N=33 3.121 1.20 0.23 No 
Y=33 1.787 
Anterior N=33 2.515 1.60 0.11 No 
Y=33 1.181 
Posterior N=32 0.625 0.05 0.95 No 
Y=33 0.606 
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TABLE VIII 
T-Test for cardiac arrhythmias and oral variables 
Variable N Mean t-value p-value Significant 
p < 0.05 
Primary Pitting N=30 0.101 -1.75 0.08 No 
Teeth Y=9 0.321 
Pinpoint N=8 82.5 -0.99 0.34 No 
Y=7 96.43 
Craters N=8 17.5 0.99 0.34 No 
Y=7 3.57 
Permanent Pitting N=35 0.675 -0.63 0.53 No 
Teeth Y=7 0.821 
Pinpoint N=32 85.57 2.39 0.02 Yes 
Y=5 67.177 
Craters N=32 14.43 -2.39 0.02 Yes 
Y=5 32.82 
Fibromas Total N=52 2.942 2.65* 0.01 Yes 
Y=12 0.833 
Anterior N=52 2.173 2.31 * 0.02 Yes 
Y=12 0.666 
Posterior N=51 0.784 2.18* 0.03 Yes 
Y=12 0.166 
* = Satterthwaite t-Test Method, variances unequal. 
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TABLE IX 
T-Test for facial angiofibromas and oral variables 
Variable N Mean t-value p-value Significant 
p < 0.05 
Primary Average N=20 0.036 -2.76 0.009 Yes 
Teeth Pitting Y=15 0.225 
%Pinpoint N=4 90 0.21 0.83 No 
Y=9 86.11 
%Craters N=4 10 -0.21 0.83 No 
Y=9 13.88 
Permanent Average N=6 0.223 -2.62 0.012 Yes 
Teeth Pitting Y=40 0.756 
%Pinpoint N=4 78.97 -0.60 0.55 No 
Y=38 84.16 
%Craters N=4 21.03 0.60 0.55 No 
Y=38 15.83 
Fibromas Total N=22 0.272 -3.32 0.0015 Yes 
Y=44 3.977 
Anterior N=22 0.045 -3.63 0.0006 Yes 
Y=44 3.068 
Posterior N=22 0.227 -1.82 0.07 No 
Y=43 0.930 
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TABLE X 
T-Test for retinal lesions and oral variables* 
Variable N Mean t-value p-value Significant 
p < 0.05 
Primary Pitting N=20 0.171 0.66 0.51 No 
Teeth Y=3 0 
Pinpoint N=7 IN IN IN IN 
. Y=O 
Craters N=8 IN IN IN IN 
Y=O 
Permanent Pitting N=17 0.75 0.48 0.63 No 
Teeth Y=6 0.613 
Pinpoint N=17 80.28 0.06 0.95 No 
Y=6 79.76 
Craters N=17 19.71 -0.06 0.95 No 
Y=6 20.23 
Fibromas Total N=33 1.969 -1.30 0.20 No 
Y=7 4.428 
Anterior N=33 1.545 -1.04 0.30 No 
Y=7 3 
Posterior N=33 0.424 -1.46 0.15 No 
Y=7 1.428 
*IN = insufficient numbers. 
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TABLE XI 
T-Test for seizures vs. no seizures and oral variables 
Variable N Mean t-value p-value Significant 
p < 0.05 
Primary Pitting N=11 0.152 0.33 0.744 No 
Teeth Y=39 0.118 
Pinpoint N=6 76.66 -0.78 0.448 No 
Y=12 89.58 
Craters N=6 23.33 0.78 0.448 No 
Y=12 10.41 
Permanent Pitting N=I7 0.644 -0.20 0.841 No 
Teeth Y=55 0.676 
Pinpoint N=16 89.104 1.24 0.217 No 
Y=51 83.579 
Craters N=16 10.896 -1.24 0.217 No 
Y=51 16.421 
Fibromas Total N=24 2.5 0.23 0.814 No 
Y=79 2.278 
Anterior N=24 1.875 0.19 0.846 No 
Y=79 1.734 
Posterior N=24 0.625 0.24 0.808 No 
N=78 0.551 
79 
TABLE XII 
T-Test for familial (F) vs. sporadic (S) TSC and oral variables 
Variable N Mean t-value p-value Significant-
p < 0.05 
Primary Pitting F = 18 0.255 1.25 0.223 No 
Teeth S=11 0.072 
Pinpoint F=8 79.375 -0.97 0.355 No 
S=3 100 
Craters F=8 20.625 0.97 0.355 No 
S=3 0 
Permanent Pitting F=29 0.713 0.75 0.459 No 
Teeth S=8 0.555 
Pinpoint F=27 84.822 0.02 0.985 No 
S=8 84.7 
Craters F=27 15.18 -0.02 0.986 No 
N=8 15.29 
Fibromas Total F=40 2.525 0.39 0.695 No 
S=15 2 
Anterior F=40 1.825 0.35 0.724 No 
S=l5 1.466 
Posterior F=40 0.7 0.36 0.72 No 
S=15 0.533 
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TABLE XIII 
T-Test for nontruncating (Nt) vs. truncating (T) mutations and oral variables 
Variable N Mean t-value p-value Significant . 
p < 0.05 
Primary Pitting Nt=7 0.152 -0.03 0.979 No 
Teeth T=17 0.155 
Pinpoint Nt=4 90 0.38 0.709 No 
T=7 82.14 
Craters Nt=4 10 -0.38 0.709 No 
T=7 17.85 
Permanent Pitting Nt=11 0.264 -0.94 0.353 No 
Teeth T=19 0.577 
Pinpoint Nt=10 84.54 0.85 0.401 No 
T=18 78.93 
Craters Nt=10 15.45 -0.85 0.401 No 
T=18 21.06 
Fibromas Total Nt=12 3.17 -0.513 0.611 No 
T=34 2.35 
Anterior Nt=12 2.42 -0.567 0.574 No 
T=34 1.74 
Posterior Nt=12 0.75 -0.242 0.588 No 
T=34 0.62 
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TABLE XIV 
Chi-square test for oral fibromas vs. systemic variables* 
Variable N Chi square Prob Significant 
AML N=15 3.31 0.0688 No 
Y=12 
PKD N=24 0.1827 0.6691 No 
Y=8 
Cardiac N=13 0.5536 0.4569 No 
Rhabdomyomas Y=13 
Cardiac N=25 0.8553 0.3551 No 
Arrhythmias Y=4 
Facial N=3 18.95 <0.0001 Yes 
Angiofibromas Y=31 
Retinal Lesions N=13 4.96 0.0258 Yes 
Y=6 
*Oral fibromas= Yes. 
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TABLE XV -Part I 
Correlation coefficients for phenotype variables vs. oral variables 
Primary Total 
Teeth Permanent Teeth Number 
Average# Average# of Pits of Oral 
of Pits Fibromas 
IQ Estimation (Pearson's Correlation) 
Correlation Coeff -0.405* 0.019 0.178 
Sig. (2-tailed) 0.050 0.932 0.285 
N 24 22 38 
# of Tubers (Pearson's Correlation) 
Avg# Pinpoint Craters 
Correlation Coeff 0.191 0.587* -0.587* -0.168 
Sig. (2-tailed) 0.217 0.495 0.035 0.035 0.466 
N 0.522 15 13 13 21 
11 
#of AED's used (Pearson's Correlation) 
Correlation Coeff -0.167 -0.079 -0.014 
Sig. (2-tailed) 0.330 0.606 0.911 
N 36 45 68 
Hx of Cardiac Rhabdomyomas (Spearman's rho) 
Correlation Coeff 0.291 -0.072 -0.084 
Sig . . (2 tailed) 0.085 0.653 0.510 
N 36 41 64 
Hx of Arrhythmias (Spearman's rho) 
Avg# Pinpoint Craters 
Correlation Coeff 0.408* 0.011 -0.344* 0.348* -0.126 
Sig. (2-tailed) 0.014 0.944 0.043 0.041 0.329 
N 36 40 35 35 62 
Presence of Angiomyolipomas (Spearman's rho) 
Correlation Coeff 0.136 0.048 0.141 
Sig. (2-tailed) 0.449 0.745 0.254 
N 33 48 67 
PKD (Spearman' s rho) 
Correlation Coeff 0.235 0.024 0.012 
Sig. (2-tailed) 0.188 0.873 0.925 
N 33 46 65 
Hypertension (Spearman's rho) 
Correlation Coeff Insufficient -0.142 0.201 
Sig. (2-tailed) Numbers 0.385 0.106 
N 44 66 
(contmued) 
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TABLE XV-Part II 
Correlation coefficients for phenotype variables vs. oral variables 
Primary Total 
Teeth Permanent Teeth Number 
Average# Average # of Pits of Oral 
of Pits Fibromas 
Retinal Lesions (Spearman's rho) 
Correlation Coeff -0.170 -0.137 0.372* 
Sig. (2-tailed) 0.462 0.543 0.020 
N 21 22 39 
Facial Angiofibromas (Spearman' s rho) 
Correlation Coeff 0.527* 0.378* 0.514* 
Sig. (2-tailed) 0.002 0.011 0.000 
N 32 44 64 
Primary Teeth Average# of Pits (Pearson's Correlation) 
Correlation Coeff NA NA 0.177 
Sig. (2-tailed) 0.239 
N 46 
Permanent Teeth Avera:re #of Pits (Pearson's Correlation) 
Correlation Coeff NA NA -0.008 
Sig. (2-tailed) 0.954 
N 60 
Permanent Teeth Percent Pinpoint Pits (Pearson's Correlation' 
Avg# Pits Craters 
Correlation Coeff NA NA NA -1.00** 0.121 
Sig. (2-tailed) <0.0001 0.655 
N 68 16 
Total Number of Oral Fibromas (Pearson's Correlation) 
Correlation Coeff 0.177 -0.008 NA 
Sig. (2-tailed) 0.239 0.954 
N 46 60 
Familial vs. Sporadic Disease 
Correlation Coeff -0.160 -0.099 -0.004 
Sig. (2-tailed) 0.416 0.595 0.980 
N 28 31 50 
Truncating vs. Nontruncating Mutations 
Correlation Coeff 0.257 -0.276 0.117 
Sig. (2-tailed) 0.215 0.147 0.439 
N 25 29 46 
84 
TABLE XVI 
Analysis of variance testing (ANOVA) for seizure severity and 
cognitive impairment vs. oral variables 
Seizure Severity Cognitive Impairment 
Variable F- p-Value Significant F-Value p-Value Significant 
Value 
Primary Pitting 0.62 0.539 No 0.78 0.514 No 
Teeth 
Pinpoint 0.40 0.6773 No 1.14 0.366 No 
Craters 0.40 0.6773 No 1.14 0.366 No 
Permanent Pitting 0.66 0.512 No 1.70 0.176 No 
Teeth 
Pinpoint 1.12 0.332 No 0.71 0.549 No 
Craters 1.12 0.332 No 0.71 0.549 No 
Fibromas Total 0.29 0.747 No 1.63 0.188 No 
Anterior 0.13 0.879 No 1.51 0.216 No 
Posterior 0.66 0.521 No 2.36 0.077 No 
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TABLE XVII 
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Cardiac Rhabdomyomas 
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TABLE XVIII-Part I 
Summary chart of statistical tests for oral findings vs. phenotype variables 
Seizure # ofTubers #ofAED's IQ Cognitive 
Activity Severity Estimation Impairment 
t-Test ANOVA Pearsons Pearsons Pearsons ANOVA Correlation Correlation Correlation 
Sig. Sig. +/- +I- +/- Sig 
Average No No No No Negative No Pitting 
Primary 
Pinpoint No No No No No No Teeth 
Craters No No No No No No 
Average 
No No No No No No Pitting 
Permanent 
Teeth Pinpoint No No Positive No No No 
Craters No No Negative No No No 
Total No No No No No No 
Fibromas Anterior No No No No No No 
Posterior No No No No No No 
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TABLE XVIII-Part II 
Summary chart of statistical tests for oral fmdings vs. phenotype variables 
Angiomyolipo- Polycystic Cardiac Cardiac 
mas (AML) Kidney Disease Rhabdomyomas Arrhythmias 
(PKD) 
Cl) ~ Cl) ~ Cl) ~ Cl) ~ 
...... 
~§ 
...... 
~§ 
...... 
~§ 
...... 
~§ 
Cl) ::l Cl) ::l Cl) ::l Cl) ::l 
~ ~.e cr ~ ~.e cr ~ ~.e cr ~ ~.e cr ~ r/( ~ r/( ~ r/( ~ CIJ ~ :a ~ :a ~ :a ~ :a 0.. 0.. 0.. 0.. 
CIJ u CIJ u CIJ u CIJ u 
Sig +I- Sig Sig +I- Sig Sig +I- Sig Sig +I- Sig 
Average No No NA No No NA No No NA No 
Posi- · NA 
Pitting tive 
Primary Pinpoint No No NA No No NA No No NA No No NA 
Teeth 
Craters No No NA No No NA No No NA No No NA 
Average No No NA No No NA No No NA No No NA Pitting 
Permanent Pinpoint No No NA No No NA No No NA Yes 
Neg- NA 
ative 
Teeth Posi-
Craters No No NA No No NA No No NA Yes tive NA 
Total No No No No No No No No No Yes No No 
Fibromas Anterior No No - No No - No No - Yes No -
. 
Posterior No No - No No - No No - Yes No -
NA Test not applicable. 
Test not performed. 
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TABLE XVIII-Part III 
Summary chart of statistical tests for oral findings vs. phenotype variables 
Facial Angiofibromas 
Primary 
Teeth 
Permanent 
Average 
Pitting 
Pinpoint 
Craters 
Average 
Pitting 
Teeth Pinpoint 
Craters 
Total 
Fibromas Anterior 
Posterior 
Sig +/-
Yes Positive 
No No 
No No 
Yes Positive 
No No 
No No 
Yes Positive 
Yes No 
No No 
IN Insufficient numbers to test. 
NA Test not applicable. 
Test not performed 
I ~ :a 
uS. 
C/) 
Sig 
NA 
NA 
NA 
NA 
NA 
NA 
Yes 
Retinal Lesions Hypertension 
Sig +I- Sig +I- Sig 
No No NA IN NA 
IN No NA IN IN 
IN No NA IN IN 
No No NA No NA 
No No NA No NA 
No No NA No NA 
No Positive Yes No 
No No No 
No No No 
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TABLE XIX 
Summary chart of statistical tests for oral findings vs. TSC 
familial and sporadic disease and mutation type 
Familial vs. Sporadic Truncating vs. 
Disease Nontruncating Mutations 
t-test Spearman's t-test Spearman's 
Sig rho Sig rho 
Average No No No No 
Pitting 
Primary Teeth Pinpoint No No No No 
Craters No No No No 
Average No No No No 
Permanent Pitting 
Teeth Pinpoint No No No No 
Craters No No No No 
I 
Total No No No No 
Fibromas Anterior No No No No 
Posterior No No No No 
90 
DISCUSSION 
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According to the revised diagnostic criteria as developed at the Tuberous 
Sclerosis Consensus Conference in 1998, to establish a definitive diagnosis of TSC, if a 
patient has only one major feature, two additional minor features are required for 
diagnosis. 16 The diagnostic criteria for establishing a definitive diagnosis of tuberous 
sclerosis include multiple randomly distributed enamel pits as well as gingival fibromas, 
both as minor features of the disease. Considering that the majority if not all adult 
patients with a definitive diagnosis of TSC have been confirmed as having random 
enamel pitting by several investigators, 34-37 and reconfmned by this investigation, along 
with a high prevalence of gingival fibromas, these clinical fmdings take on significant 
importance. 
This study found pitting in 29 percent of patients between 1 and 6 years of age, in 
90 percent between 6 and 13 years of age, and in 1 00 percent of patients in the permanent 
dentition. The pits were randomly distributed and without contralateral symmetry. 
Additionally, there was a very significant negative correlation between the percent of 
pinpoint sized pits and percent of crater sized pits affecting the permanent dentition. 
There was a strong tendency for these patients to have either a predominance of pinpoint 
sized pits or crater sized pits, but not both. There was also a tendency for greater pitting 
in the maxillary permanent central incisors (78 percent) than in other teeth. This finding 
is significant in that examination of these teeth after dye stain is a bit easier than 
examining mandibular teeth or teeth positioned more posterior in the arch, especially in 
cognitively impaired individuals. Because of the logistics associated with the clinical 
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examination of these patients in many centers, obtaining a dental examination by a dentist 
may be difficult if not impossible to arrange. Knowing that the majority of pitting occurs 
in the maxillary anterior region of the mouth should aid non-dentally trained individuals 
in surveying the dentition for enamel pitting. 
It is important to remember that enamel pitting is a form of hypoplasia and is not 
pathognomonic of tuberous sclerosis. There are forms of enamel pitting associated with 
other conditions that must be considered when completing an oral evaluation. 
Individuals responsible for the oral evaluation of these patients should be well versed in 
the etiologies and appearances of various types of enamel pitting. 
In this investigation, there were only a few patients with oral fibrous lesions in 
areas other than the gingiva. One patient displayed lesions on the mandibular labial 
mucosa, another on the buccal mucosa bilaterally, while one patient had lesions on the 
dorsum of the tongue. Because of the infrequent fmding of nongingival oral lesions, 
these lesions were not tabulated for statistical purposes. 
Gingival fibromas are not commonly seen in the general population. These 
lesions must be differentiated from gingival hyperplasia secondary to drug use (e.g. 
phenytoin, cyclosporin, calcium channel blocking agents), from hereditary gingival 
fibromatosis, from fibromatoses as an aggressive infiltrative connective tissue lesion, 71 
from infective gingival pathology, and from normal variations in gingival anatomy. Each 
has a characteristic appearance making differentiation fairly straight forward; however, at 
times, trying to discern among various etiologies can be a challenge and ultimately is 
subjective. There were very few instances among the study subjects that identifying 
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TSC-related gingival fibrosis was questionable. Again, as with evaluating enamel pitting, 
the examiner should be well-educated in the differential diagnosis of gingival lesions. 
Many of the manifestations of tuberous sclerosis are age-dependent. Facial 
angiofibromas, ungual fibromas, renal angiomyolipomas appear later in childhood or 
early adulthood, 33 while cardiac rhabdomyomas are frequently seen in infancy and tend 
to regress with age. Both enamel pitting and gingival fibromas are also age dependent. 
The height of enamel pitting occurs after the transition from the mixed dentition to the 
permanent dentition, and gingival fibromas are seen most frequently after 10 year~ of 
age. 
There were few significant findings relating the degree and severity of enamel 
pitting to other physical findings of TSC, and none of the correlations were particularly 
strong. Enamel pitting was unrelated to seizure activity, number of antiepileptic drugs 
taken, cognitive impairment, angiomyolipomas, polycystic kidney disease, cardiac 
rhabdomyomas, retinal lesions or hypertension. In subjects with affected primary teeth, a 
greater degree of pitting was seen among patients with a lower estimation ofiQ score. 
The same relations was not seen with permanent teeth, however. There was a positive 
relationship between the degree of pitting in both primary and permanent teeth with the 
presence of facial angiofibromas. The only relation between pit severity and disease 
variables was seen with pinpoint-sized pits in the permanent teeth and the total number of 
cortical tubers. The degree of pinpoint pits increased along with the total number of 
tubers. Unexpectedly, the reverse was true for crater-sized pits. Most of these relations 
are not surprising, considering the ectodermal origin of the involved tissues and that 
tuberous sclerosis is in fact a neurocutaneous disease. 
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In relating gingival fibromas with other physical findings, Lygikadis reported that 
large gingival fibromas affected more severely TSC-affected patients.43 The article did 
.not, however, define the criteria for severely affected TSC patients. This investigation 
failed to find meaningful associations between gingival fibromas and other symptoms 
associated with severe disease. As with enamel pitting, there was a significant positive 
correlation, however, with the appearance of gingival fibromas (regardless of size) and 
the appearance of facial angiofibromas. From preliminary unreported data gathered at 
this institution, there does not appear to be a relation between severity of facial 
angiofibromas and overall severity of TSC disease. There was a positive, but less 
significant, correlation between gingival fibromas and retinal lesions. Because of limited 
data, retinal lesions were all grouped into one category and not broken down into specific 
type. There were no other significant fmdings relating gingival fibromas to other TSC 
disease variables. 
T.wo-thirds of individuals with TSC are thought to occur from sporadic mutations 
with over 80 percent at the TSC2locus.4 In familial cases, there is a more equal 
distribution between TSCl and TSC2 mutations. Of the 53 subjects where inheritance 
had been established, 72 percent were determined to be familial. This discrepancy may 
reflect patient sampling as well as the ability of our clinic coordinator to successfully 
recruit family members for examination. This may also suggest that more people could 
be affected with familial TSC than originally thought. It has been reported that familial 
TSC individuals are less severely affected than those with sporadic TSC.4 This is 
certainly true regarding cognitive ability and may relate to better reproductive fitness 
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among familial TSC. In evaluating enamel pitting and gingival fibromas however, there 
were not distinctions that could be made between familial versus sporadic TSC. 
In regard to genotype-phenotype observations, only patients with TSC2 mutations 
were included due to the small number of patients with TSC 1 mutations. Out of 104 
study subjects, only 6 were associated with TSC1 mutations. This number is clearly 
reflective of sampling characteristics and is not an accurate representation of the TSC 
population as a whole. Additionally, because of a limited number of each type of 
mutation, mutations were grouped into one of two categories. Those mutations that 
resulted in a stop codon leading to premature termination of tuberin (small deletions or 
insertions, nonsense, splice site, and frameshift mutations) were classified as truncating 
mutations. Large genomic deletions were also included in this category because the 
effect is essentially the same as truncation. Mutations that did not lead to premature 
termination oftuberin (missense mutations and in-frame deletions) were classified as 
nontrunGating mutations. There were no TSC2 genotype-phenotype correlations found 
with enamel pitting and/or gingival fibromas. These results were not surprising 
considering the tremendous variability in expression of the disease. This parallels other 
investigations that have not found TSC2 genotype-phenotype correlations with other 
disease variables. 52 
Future research regarding oral manifestations and the relationship to overall TSC 
disease is needed. Additional studies should concentrate on 1) examining a large enough 
patient pool to correlate oral fmdings in TSC 1 and TSC2 individuals, 2) cohort studies to 
examine the changes in oral symptoms over time in individuals, 3) including better 
imaging of the maxillary and mandibular complex using panoramic radiographs, CT or 
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MRI scans to evaluate for the occurrance of intraosseous fibrous lesions as reported by 
Damm, 45 and fmally, 4) animal studies to investigate the process of enamel formation and 
the role of the tuberin and hamartin on ameloblast function. 
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SUMMARY AND CONCLUSIONS 
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The purpose of this investigation was to study the incidence of enamel pitting and 
gingival fibromas in patients with a definitive diagnosis of tuberous sclerosis complex 
and relate these findings to other symptoms of TSC, to familial and sporadic disease, and 
specific TSC2 mutations. There have been no reports relating oral findings to these 
specific variables. 
Subjects were recruited from the Tuberous Sclerosis Clinic at Children's Hospital 
Medical Center, Cincinnati, Ohio and all had a definitive diagnosis of tuberous sclerosis. 
A total of 1 04 patients ranging in age from 1 to 51 years of age were examined in the 
neurology clinic for the presence of enamel pitting and gingival fibromas. Subjects 
initially either brushed their own teeth or had their teeth brushed to remove existing 
plaque. The dentition was then stained with Trace disclosing solution (Red dye #28) 
using a 6 inch cotton swab and examined using a dental explorer and lighted mirror 
(DenLite by WelchAllyn). A standardized examination form was used for data collection 
(see Appendix I). Data collected included the total number and location of pits per tooth, 
size of pits, and location and number of gingival fibromas. The data were then entered 
into databases for tabulation and analysis. 
Patients participating in the study already had extensive testing as part of a larger 
IRB approved investigation at Children's Hospital Medical Center entitled 
"Genotype/Phenotype Analysis of Individuals with Tuberous Sclerosis and Their Family 
Members". Test results made available for this investigation included MRI scans of the 
brain, echocardiography, renal ultrasound, neuropsychological assessments, and results of 
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retinal examinations. All study subjects had one blood sample taken for DNA extraction 
that was completed at Children's Hospital in Cincinnati. The DNA samples were then 
. sent to Brigham and Women's Hospital in Boston, Massachusets for mutational analysis 
of either of the tuberous sclerosis genes. These results were then made available to 
investigators at Children's Hospital in Cincinnati. Based upon this information along with 
an evaluation by a geneticist, mutations were classified as being either familial or 
sporadic. 
In evaluating the characteristics of enamel pitting, the majority of pits were 
pinpoint sized affecting the maxillary more often than the mandibular arch and most of 
the pits were anterior to the maxillary canine. The maxillary central incisor was the most 
often affected permanent tooth, while the maxillary canine was the most often affected 
primary tooth. Patients also had a tendency for a predominance of either pinpoint sized 
pits or crater sized pits. 
Jhe study found enamel pitting in 29% of patients between 1 and 6 years of age, 
in 90% between 6 and 13 years of age, and in 1 00 percent of patients in the permanent 
dentition. Because of the small number of patients under the age of six that displayed 
enamel pitting, its usefulness as a minor feature in the diagnosis of TSC is more limited. 
The overwhelming majority of oral fibromas appeared on the maxillary anterior 
gingiva affecting the interdental papilla. Gingival fibromas were less likely to be seen in 
children under the age of six, and seemed to significantly increase in numbers after 1 0 
years of age. In this study, 4 7% of individuals in the mixed dentition had gingival 
fibromas while 70% of individuals in the permanent dentition were affected. 
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There were very few significant findings relating the degree and/or severity of 
enamel pitting or gingival fibromas to other physical findings of TSC and none of the 
. correlations were particularly strong. There was a positive correlation between the 
average number of pits in primary teeth with the presence of cardiac arrhythmias as well 
as for those individuals with a tendency toward crater sized pitting in the permanent 
teeth. There were also significant positive relationships between the appearance of facial 
angiofibromas with the average number of enamel pits in primary and permanent teeth, as 
well as with the presence of gingival fibromas. The only other significant finding was a 
positive correlation between the total number of gingival fibromas and retinal lesions. 
In comparing oral fmdings to sporadic and familial TSC disease, no distinctions 
were evident between the two groups. Likewise, there were no TSC2 genotype-
phenotype correlations found with enamel pitting or gingival fibromas. 
Despite the lack of significant genotype-phenotype correlations with oral fmdings, 
enamel, pitting and gingival fibromas are important features of the disease. Together, the 
combination of enamel pitting along with gingival fibromas, as minor features of TSC, 
should significantly raise the suspicion level regarding tuberous sclerosis as a diagnosis. 
Scanning the dentition and gingiva is noninvasive, inexpensive, easy to learn, and should 
be included in evaluating all patients suspected of a diagnosis of tuberous sclerosis. 
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ABSTRACT 
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TUBEROUS SCLEROSIS-ASSOCIATED ENAMEL PITTING AND GINGIVAL 
FIBROMAS: FAMILIAL VS. SPORADIC DISEASE· 
' 
GENOTYPE-PHENOTYPE CORRELATIONS 
by 
Murray Dock 
Indiana University School of Dentistry 
Indianapolis, Indiana 
The purpose of this investigation was to study the incidence of enamel pitting and 
gingival fibromas in patients with tuberous sclerosis complex (TSC) and relate these 
findings to other physical findings of TSC, to sporadic and familial disease, and to 
specific TSC2 mutations. 
Methods: A total of 1 04 patients between 1 and 51 years of age were examined 
for enamel pits and gingival fibromas. All study subjects had a definitive diagnosis of 
TSC and were participants in a related study that provided results from MRI scans of the 
brain, echocardiography, renal ultrasound, neuropsychological assessments, and retinal 
examinations. Blood samples were obtained from each participant for DNA extraction 
and subsequent TSC mutational analysis. 
Results: Enamel pitting was seen in 29% of patients between 1 and 6 years of 
age, in 90% between 6 and 13 years of age, and in 1 00% of patients in the permanent 
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dentition. The majority of the pits were pinpoint sized and primarily affected the 
maxillary anterior arch. The maxillary central incisor was the most often affected 
permanent tooth and the maxillary canine was the most often affected primary tooth. 
Gingival fibromas were apparent in 47% of subjects in the mixed dentition and in 70% of 
subjects in the permanent dentition. Only one patient out of 31 in the primary dentition 
had a gingival fibroma. The majority of fibromas affected the interdental papilla of the 
maxillary anterior arch. There were few significant findings relating the degree and/or 
severity of enamel pitting and/or gingival fibromas to other physical findings of TSC. 
Enamel pitting in primary as well as permanent teeth were found to be strongly related to 
the presence of facial angiofibromas and a somewhat weaker association was seen with 
cardiac arrhythmias. Gingival fibromas were strongly related to the presence of facial 
angiofibromas and more weakly related to retinal lesions. There were no distinctions 
apparent between oral findings in sporadic and familial TSC nor were there any 
genotype-phenotype correlations between oral findings and TSC2 mutations. 
Conclusion: The combination of enamel pitting and gingival fibromas, as minor 
features of TSC, should raise the suspicion level regarding tuberous sclerosis as a 
diagnosis. Both are important minor features frequently seen which may help in 
establishing a defmitive diagnosis. Scanning the dentition and gingiva is noninvasive, is 
inexpensive, and should be included in evaluating all patients suspect of a diagnosis of 
tuberous sclerosis. 
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